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Abstract 
 
Human papillomavirus infection is the cause of more than 99% of cervical cancer 
cases.  The current vaccine is ineffective therapeutically; highlighting the need for 
continued papillomavirus research.  One avenue that could be explored in this 
regard is the function of the papillomavirus E2 regulatory proteins.  HPV E2 
represses expression of the viral E6 and E7 oncoproteins.  Reintroduction of E2 
into cervical carcinoma cells results in growth arrest and cellular senescence.  
Understanding the mechanism of how E2 regulates the early promoter may be 
key to developing new therapeutic and prophylactic vaccines.  
Here, we describe regulation of E2 through acetylation and possibly through 
direct interaction with a novel cellular interacting protein, RINT1.  Histone 
acetyltransferase (HAT) proteins have been demonstrated to interact with Bovine 
Papillomavirus (BPV) and Human Papillomavirus (HPV) E2 proteins as well as 
enhance E2 dependant transcription luciferase reporter plasmid containing E2 
binding sites.  We demonstrate that HATs p300, CBP, and pCAF are limiting for 
E2 dependant transcriptional activation and that each protein functions 
independently.  We have also identified that BPV-1 E2 is a substrate for 
acetylation by p300.  Mutants of E2 that cannot be acetylated on lysines 111 or 
112, display abnormal transcriptional phenotypes.  Cells deficient in p300 display 
similar transcriptional defects that are intensified by CBP depletion.  We propose 
that acetylation of BPV-1 E2 is necessary for transcriptional activation.  
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Acetylation generates a binding site through which a co-factor may interact via a 
bromodomain.  Regulation of E2 dependent transcriptional activation through a 
post-transcriptional modification represents a novel method through which BPV-1 
controls gene expression.  
We also present evidence for a direct interaction between BPV-1 E2 and the 
cellular factor RINT1.  This interaction does not appear to be critical for 
transcriptional regulation; however, several other functional pathways are 
indicated by the cellular complexes in which RINT1 functions.  Some of these, 
such as ER/Golgi vesicular transport and hTERT independent telomere 
maintenance, are pathways in which E2 has no known role.  Further investigation 
into regulation and consequences of E2 acetylation and the biological 
significance of the interaction between E2 and RINT1 could prove important in 
understanding the complex role of E2 in papillomavirus infection.  
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Papillomaviruses and Human Disease 
Papillomaviruses (PV) are small non-enveloped viruses that infect dividing cells 
in the basal epithelia.  Viral genetic information is encoded on a double stranded 
circular DNA genome of between seven and eight kilobases (kb).  Despite a 
small genome size, PVs exhibit a high level of diversity.  189 PV types have been 
identified as of a report in 2010 with 120 types infecting humans, 64 infecting 
non-human mammals, 3 infecting birds, and 2 types infecting reptiles (17).  Virus 
types are categorized by sequence divergence of the L1, E6, and E7 reading 
frames (17, 201).  Viruses with greater than 60% L1 nucleotide sequence identity 
are grouped into genera designated by Greek letters (17).  Unique virus types 
are defined as having greater than 10% L1 sequence divergence from any other 
type (39).  Human papillomaviruses (HPV) are clustered into five (alpha, beta, 
gamma, mu, and nu) out of the existing 29 genera (17).  Each virus type exhibits 
high species and tissue specificity (31).  It is thought that this specificity is due to 
viruses co-evolving with their hosts and that restriction may involve viral 
interactions with host specific factors (169).  Transmission generally occurs from 
direct contact with infected tissues; however, PVs are relatively robust in the 
environment owing to a non-enveloped capsid.  This is illustrated by their ability 
to retain 30% infectivity following dehydration for seven days (155) and thus 
transmission via inanimate intermediaries is possible.   
Human papillomavirus (HPV) infection of epithelial tissue causes an abnormal 
proliferation of basal cells into the upper layers of the epithelium.  This manifests 
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as a benign tumor or wart.  Infection can take place in both cutaneous and 
mucosal tissue.  Cutaneous warts are common in older children and young 
adults with prevalence of up to 33% in primary school children (195) and only 
3.5% in adults (18).  These lesions typically regress spontaneously due to 
immune clearance; however, in some cases they can persist for years if 
untreated.   
Epidermodysplasia verruciformis (EV) is a rare autosomal recessive skin 
condition characterized by the abnormal susceptibility to cutaneous, beta-HPVs 
(most often HPV-5).  Papillomavirus infection in EV patients results in persistent 
warts that progress to carcinomas in about half of the cases (90).  EV is now 
thought to be due to a primary immunodeficiency (140).  Homozygosity mapping 
of three families, led to mapping of a predisposition locus on chromosome 
17q25.3 and subsequent identification of two adjacent genes (EVER1 and 
EVER2) that segregated with the disease (151).  These genes were found to 
code for ER resident transmembrane proteins that complex with the ZnT-1 zinc 
transporter (111).  The authors hypothesize that the susceptibility of EV patients 
to beta-PV infection is related to the E5 protein.  They find that the EVER/ZnT-1 
complex is inactivated by the HPV-16 E5 protein; beta-HPVs do not encode E5, 
and are restricted by the EVER/Znt-1 complex (111).  The zinc imbalance caused 
by the lack of the EVER/Znt-1 complex in EV patients results in reduced 
production of proinflammatory cytokines (111) which may account for the high 
prevalence of carcinoma in HPV-5 EV associated lesions. 
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Clinical and subclinical infection of mucosotropic HPVs in the genital tract 
accounts for one of the most prevalent sexually transmitted diseases in United 
States and the world (9, 190).  Viruses of this category are further subdivided into 
low risk and high risk groups based on the clinical severity of disease.  Infection 
with low risk viruses produces genital condylomas or warts.  These lesions, like 
cutaneous warts, are generally cleared by the host immune system.  Infection 
with viruses of the high risk group also has a high probability of clearance; 
however, persistent infection with high risk viruses such as HPV-16, HPV-18, or 
HPV-31, may progress to a carcinoma.  Further, persistent infection with high risk 
HPV types is the definitive cause of cervical carcinomas with greater than 99% of 
cases involving infection with HPV (198). 
High risk HPV types are also found with high incidence with other mucosal 
cancers.  Studies have found HPV associated with cancers of the oropharynx, 
anus, vulva, vagina, and penis at a prevalence of between 36% and 93% of all 
recorded cases (60).  Of those associated with HPV, a much higher proportion of 
those cancers contained types HPV-16 and HPV-18 (86% to 95%).  A higher 
prevalence than even cervical cancer (76%) (60).  Several observations were 
made based on the prevalence and demographic data presented.  First, the 
incidence of non-cervical HPV related cancers represents a higher proportion of 
total HPV related cancers in regions where adequate cervical screening 
procedures, such as Pap smear, are in place.  Second, there appears to be 
equal incidence of HPV related non-cervical cancers in male and female 
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populations, and finally oropharyngeal cancers are more prevalent in men and 
make up a substantial population of the total HPV related cancers, second only 
to cervical (60). 
In 2008 there were estimated to be 529,000 new cases of cervical cancer 
worldwide (52).  This makes it the third most common cancer in women and the 
seventh overall.  The number of diagnoses increased from the previous report; 
however, increased screening is probably the cause for this.  85% of the total 
incidence of cervical cancer was in developing countries and 88% of the total 
deaths from cervical cancer were also in these regions.  There were 275,000 
deaths worldwide which was equal to the number reported in 2002 (52).  The 
staggering prevalence in the developing world is not unsurprising.  The 
probability of infection increases with the number of sexual partners and 
incidence of cervical cancer is higher in regions where screening procedures are 
lacking or absent.  Prior to development of screening programs in the 1960’s and 
1970’s the incidence in Europe, North America, and Australia were as high as 
those in developing countries today (144).  
The recent release of two vaccines to HPV may result in a decrease in incidence 
in cervical cancer in all populations.  Gardasil®, released by Merck was raised 
from virus like particles (VLP) from HPV types 6, 11, 16, 18 and Cervarix™, by 
Glaxo-Smith-Kline was raised against HPV types 16 and 18.  Both vaccines 
performed well in the trials under the prescribed course demonstrating effective 
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prevention of lesions in immunized subjects for a period of four years (170).  
However, these vaccines have limited cross type prophylactic efficacy and are 
not effective therapeutically (160).  Despite their shortcomings, the trial reports 
indicate that there would be a health benefit from vaccination, although this 
benefit would not be inexpensive.  Each dose would cost $130 per injection or 
$390 for the entire series (170).  This cost would mean that uninsured or under-
insured individuals would most likely not be able to see the benefits from such a 
vaccine.  Additionally, the associated cost and the availability for distribution 
would likely prevent a benefit in the developing world where it is most needed.  
The financial burden associated with distribution of the current vaccine and the 
ineffectiveness for treating infected patients therapeutically highlights the need 
for continued investigation into new therapies and treatments for HPV and 
cervical cancer. 
Papillomavirus Infection  
Papillomavirus genomes from different virus types are similar in their size as well 
as genomic organization.  Each genome consists of an average of nine open 
reading frames encoding early genes (E1, E2, E4, E5, E6, E7, and E8) and late 
genes (L1 and L2) (Fig 1.1).  These gene sets are grouped on opposite sides of 
the viral genome and are separated by approximately 1 KB of non-coding 
sequence known as the long control region (LCR) or upstream regulatory region 
(URR).  The LCR contains several promoters controlling early and late gene 
expression, a constitutive transcriptional enhancer element, the viral origin of  
7 
 
 Figure 1.1 Diagram of the BPV-1 genome BPV-1 genomic organization 
showing the early genes on the right side of the genome, and the 
late genes on the left.  The intervening sequence is called the long 
control region (LCR), it contains several early promoters, the late 
promoter, a minichromosome maintenance element and the viral 
origin of replication. Figure from reference (173), used with 
permission. 
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replication, and the minichromosome maintenance element.  The icosahedral 
capsid consists of 72 L1 capsomers (11).  The minor capsid protein L2 is present 
at one thirtieth the abundance of L1 and is largely internal (179).  L1 alone is 
capable of forming VLPs; however, L2 is also incorporated upon its expression 
(72, 98, 216).  Papillomaviruses infect the dividing cells in the basal epithelium.  
The virus is thought to gain access to these cells through wounding of the skin.  
Initial attachment is thought to be through heparin sulfate proteoglycans (HSPG) 
(62, 92).  Studies have shown that attachment and infection can be blocked by 
treatment with heparinase, soluble heparin, or sulfated polymers such as 
carrageenans (28, 62, 92).  Studies show that virion attachment is not on the 
epithelial cell surface but on the basement membrane that has been exposed 
through wounding (154).  One hypothesis is that PVs have evolved to specifically 
bind to HSPGs on the basement membrane to allow preferential interaction with 
the dividing basal epithelial cells during wound healing.  Attachment to the 
basement membrane exposes the capsid to cleavage by furin protease which 
cleaves the minor capsid protein L2 (153).  Cleavage of L2 induces a 
conformational change in L1 that exposed a new region of L1 that interacts with a 
second receptor on the epithelial cells (161). 
Following initial attachment to the basement membrane or basal epithelial cells, 
there is a long delay (12-24 hours) prior to detection of productive infection (36).  
There is a great deal of controversy about the mode of internalization between 
different virus types and even between different reports on the same virus type.  
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Studies have demonstrated that internalization of some viruses is clathrin 
dependent (23, 38, 78, 108), others enter via caveosomes (23, 175), others 
argue for a hybrid of these pathways (108).  One recent study using siRNA 
mediated depletion and dominant negatives for both clathrin and caveolar-
endocytosis claims that HPV internalization is independent of both clathrin and 
caveolin and might be internalized via a novel pathway involving tetraspanin-
enriched microdomains (178).  Internalization is followed by trafficking into late 
endosomal compartments (38) where L2 is required for endosomal escape (94).  
Finally, through a poorly understood mechanism, the viral genome and L2 are 
trafficked through the cytosol, probably by dynein microtubule motors, and into 
the nucleus (54, 164).  Once in the nucleus L2 and genomes are localized to 
promyelocytic leukemia (PML) rich ND10 domains (37) where primary 
transcription commences. 
Productive Virus Life Cycle 
The papillomavirus life cycle is tightly linked to the differentiation program of the 
epithelial cells where infection occurs (Fig 1.2).  As mentioned previously, initial 
infection takes place in the basal stem cell layer of the epithelium. These cells 
divide and become transit amplifying cells, which are capable of several more 
rounds of division prior to differentiation (200).  These two groups of cells contain 
the only actively dividing cells within epithelial tissue.  After an initial burst of early  
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 Figure 1.2 The papillomavirus life cycle is linked to differentiating 
epithelia.  Papillomaviruses infect through wounding to the basal 
epithelial stem cells. There, they replicate approximately once per 
cell cycle. As cells differentiate and move up into the stratum 
spinosum, E6 and E7 maintain the cell in a proliferative state 
which allows the virus to amplify its genome and activate late gene 
expression. Further up in the stratum granulosum, the capsids are 
assembled with genomes and in the stratum corneum, cells and 
virus are lost to sloughing. Figure from reference, used with 
permission (77). 
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gene expression, the virus begins initial genome amplification where it increases 
copy number to approximately 50 to 100 genomes per cell (93).  It then continues 
expressing early proteins necessary for genome replication and the viral genome 
replicates approximately once per cell cycle as a stable extra-chromosomal 
element or episome (110).  Viral early proteins E1 and E2 are both required for 
viral replication and E2 is necessary for episomal maintenance (69, 193).  
Replication of the BPV-1 genome in vitro requires only the viral E1 protein (20), 
although replication is more efficient with the addition of E2 (21).  The roles of E1 
and the E2 DNA binding regulatory factor in replication and maintenance will 
briefly be discussed here.  The role of E2 in transcriptional regulation will be 
discussed at length elsewhere. 
E1 protein is a nuclear phosphoprotein that encodes ATPase and helicase 
activity (24, 168).  It specifically recognizes the viral origin of replication (194), 
although at low affinity.  Efficient recruitment of E1 to the viral origin requires 
complex formation with the viral E2 protein which acts as a specificity factor (21).  
It is thought that the nonspecific DNA binding activity of the helicase domain 
necessitates E2.  E2 interacts though its N-terminal domain to the helicase 
domain on E1.  This interaction inhibits the ability of the helicase domain to 
interact with DNA (180).  Following E2/E1 dimer association with the origin, 
additional E2/E1 complexes are added until an E1 tetramer is present.  E2 is lost 
through an ATPase dependent step and the tetramer converts to a head to head 
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double trimer which begins to melt and unwind DNA.  E1 continues polymerizing 
until a double hexamer forms on the origin (165).  
The mechanism by which papillomaviruses maintain stable copy numbers in 
dividing cells is relatively unclear.  It is known that papillomaviruses replicate by a 
“relaxed” random choice method, each genome is replicated on average once 
per cell cycle.  The level of replication may take several factors into account, 
including cell specific factors and the expression level of E1 (80).  Another factor 
may be the phosphorylation status of E1.  Phosphorylation of E1 by cyclinA/cdk 
and cyclinE/cdk complexes is important for E1 localization (41, 82).  Shuttling of 
E1 out of the nucleus during S-phase may control the level of replication (82). 
In addition to replication of the genome and maintenance of genome copy 
number, segregation of the genome into daughter cells in mitosis also requires 
the E2 protein (87, 173).  The mini-chromosome maintenance element, which 
consists of a series of six E2 binding sites within the BPV-1 LCR, is responsible 
for tethering the viral genome to the host cell chromosomes through E2 (147).  
Several groups have identified adapter proteins which serve to tether E2 to the 
host DNA.  One report indicates that the double bromodomain containing protein 
Brd4 may be such a protein (210).  A subsequent report from our group 
demonstrates that the cellular chromatid cohesion establishment factor hCHLr1 
interacts with several E2 proteins from HPV types 11 and 16 as well as with 
BPV-1 and tethers BPV-1 genomes to the host chromosomes (143).  This 
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indicates that interaction of E2 with chromosomes is complex and may not 
consist of a one to one interaction with one adaptor protein.  Further, several 
different adaptors may be used to tether different viruses.  One report indicates 
that HPV type E2 proteins may localize to the spindles instead of the 
chromosomes during mitosis (196). 
Transit amplifying cells are committed to differentiation.  After several more 
divisions, one daughter cell moves upward from the basal into the suprabasal cell 
layers (200).  Here, cells withdraw from the cell cycle and begin to differentiate 
(200).  Papillomaviruses do not encode a DNA polymerase or any other 
replicative factor.  As the cell begins to differentiate and withdraw from the cell 
cycle, the viral oncoproteins, E6 and E7, are required to induce the cell to 
continue proliferating and expressing factors that are needed for viral genome 
replication (53, 58). 
The main function of the HPV E7 protein in the productive viral life cycle is the 
binding and degradation of pRB and its related pocket protein family members 
p107 and p130 (48, 163).  Interaction with pRB is mediated through the LxCxE 
motif in conserved region 2 of E7 (32).  pRB and its family members regulate cell 
cycle progression through their interaction with the E2F family of transcription 
factors.  E2F proteins activate transcription of many genes that control cellular 
DNA replication.  During normal cell cycle progression, pRB is phosphorylated by 
cyclin/cdk complexes at the beginning of S-phase.  This phosphorylation results 
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in the release of E2F which is then able to activate S-phase genes (49, 201).  In 
the context of HPV infection in differentiating tissue, cells are withdrawing from 
the cell cycle and pRB is no longer phosphorylated.  E7 abrogates this need 
through degradation of pRB inducing cell cycle reentry (32).  In addition to 
degradation of pRB, an E7 interaction with histone deacetylases (HDAC) has 
been shown to increase transcriptional activation of E2F targets (125).  E7 
interaction with cyclin/cdk2 complexes (129, 189) and the cyclin dependent 
kinase inhibitors (CKI) p27kip1 (211) and p21cip1 (55) all promote cell cycle 
progression. 
The major function of the papillomavirus E6 protein is primarily to bind and 
degrade the tumor suppressor p53 (159).  Aberrant reentry into the cell cycle in 
the absence of mitogens and signaling causes cellular stress which increases 
levels of p53 and induces p53 dependent cell cycle arrest or apoptosis (81, 142). 
Expression of E6 counteracts this response.  E6 forms a complex with p53 and a 
cellular E3 ubiquitin ligase, E6AP (84).  E6AP, which does not interact with p53 in 
the absence of E6, induces its poly-ubiquitination and subsequent proteosomal 
degradation (83, 85).  Another important role for E6 is the activation of 
telomerase through its catalytic subunit hTERT (99, 131).  E6 can interact with 
the cellular transcription factor c-myc and recruit it to the hTERT promoter 
increasing hTERT expression (197).  Chromosomal telomeres shorten on every 
cell division eventually resulting in cellular senescence (123).  Activation of 
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telomerase through E6 abrogates this process extending the life of the dividing 
cells.   
While expression of E6 and E7 is beneficial to the replication of papillomaviruses 
in differentiating cells, these two proteins are the primary causes of cancer in 
HPV infected cells.  Expression of E6 and E7 is controlled by the viral regulatory 
factor E2 (through a mechanism discussed in a later chapter).  In carcinomas, 
the HPV genome is often integrated into the host DNA (35).  This occurs in 
genetically fragile areas in host chromosomes (188) and generally results in 
disruption of the E2 open reading frame (91, 157).  Integration and loss of E2 
expression results in increased E6/E7 mRNA stability and loss of E2 mediated 
inhibition of immortalization (91, 157).  
As cells progress upward through the stratum spinosum, differentiation triggers 
the viral late promoter which induces expression of the capsid proteins L1 and 
L2.  The virus also transitions from maintenance replication mode to vegetative 
genome amplification.  In the stratum granulosum cells undergo nuclear 
envelope break down and the virus assembles capsids and packages the 
genome. Finally, in the superficial layer of the stratum corneum cell function 
ceases and the cells and virus are sloughed off with environmental contact (77, 
86, 124). 
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Viral Transcription and the E2 Protein 
Like replication, transcription of the viral genome depends upon the 
differentiation state of the infected epithelial cell.  It also depends upon the 
presence of a variety of cellular transcription, splicing and RNA processing 
factors (124).  Gene expression from the early promoter is controlled on a basal 
level by a number of cellular transcription factors including TFIID, Sp1, Oct1 and 
AP1 (34, 73, 158, 186).  Papillomavirus transcription is relatively complex, owing 
to multiple promoters, and multiple and alternate splicing pattern of each 
transcript.  Seven promoters and more than 20 polycistronic mRNAs have been 
identified in BPV-1 transformed cells (2, 10).  Each transcript has potential to 
code for multiple proteins; however some expressed proteins are undetectable in 
cells.  In addition to binding sites for cellular transcription factors, the LCR also 
contains specific sites for the viral E2 protein. 
The papillomavirus E2 protein is a regulatory factor that is involved in every stage 
of the productive viral life cycle (50, 124).  The E2 open reading frame of BPV-1 
encodes a 48 kDa phosphoprotein (106).  This protein contains two functional 
domains (Fig 1.3).  The N-terminal 216 amino acids of BPV-1 E2 represent the 
transactivation domain (TAD) (61).  This domain is responsible for most of the 
protein interaction between E2 and other viral and cellular factors.  The functional 
consequence of many of these interactions and the mechanisms of E2 
dependent transcriptional regulation will be discussed in a later chapter.  The C-
terminal 124 amino acids represent the DNA binding domain (4, 61).  Between 
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 Figure 1.3 Diagram of BPV-1 E2 domain organization.  The BPV-1 E2 
protein is approximately 48 kilodaltons and contains 3 domains. 
An N-terminal transactivation domain and a C-terminal DNA 
binding and dimerization domain separated by a flexible hinge 
region.  Two shorter forms are expressed which contain the C-
terminal domain but a shortened, non-functional N-terminal 
domain.  Two phosphorylation sites at serines 298 and 301 are 
present in the hinge region. 
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the two domains is a relatively unstructured and flexible hinge region (61).  
Through interaction with DNA and cellular factors, E2 can either activate or 
repress the viral early promoter including its own expression (128).  In addition to 
full length E2, two other forms of E2 are found in transformed cells.  These 
shorter proteins, called E2 repressor (E2R) and E8^E2C are 31 and 28 kDa 
respectively.  E8^E2C is an alternative splice product containing eleven amino 
acids from the E8 reading frame spiced to the 204 amino acids from the C-
terminus of E2 (106).  E2R is transcribed from a start site at within the E2 reading 
frame and encodes amino acids 162-410 (107).  Both of these proteins lack a 
complete N-terminal TAD and negatively regulate the viral early promoter.   
E2 interacts through its DNA binding domain with the specific sequences 
(ACCGN4CGGT) within the viral LCR  (4).  One of the major differences between 
BPV-1 and HPV type genomes is the number and location of these sites within 
the genome.  BPV-1 contains 17 total E2 binding sites, of which 12 are located 
within the LCR (120) whereas HPV-16 encodes only four sites.  The E2 protein 
binds to DNA as a dimer (128, 149) which primarily occurs through its C-terminal 
DNA binding domain, although dimerization has been reported in the TAD as well 
(100).  N-terminal dimerization is thought to induce DNA looping in order to 
stabilize distal enhancer elements within the initiation region (5).  E2R and E8^2C 
which contain intact DNA binding domains may also interact with and compete 
for binding site occupancy with full length E2.  E2 is also capable of forming 
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heterodimers with either of the two shorter forms resulting in a repressive 
complex (46, 135).    
E2 function appears to be regulated by post-translation modification.  
Specifically, phosphorylation of BPV-1 E2 has been reported to have a number of 
effects on its roles in the viral life cycle.  Inhibition of phosphorylation on serine 
301 by mutation to alanine induces replication to levels 20 fold higher than wild 
type E2 (127).  Another report demonstrated that while mutation of several 
phosphorylation sites increased replication in transient assays, mutant genomes 
were defective for transformation and stable maintenance (118, 119).  More 
recent evidence indicates that phosphorylation does not affect the interaction 
with mitotic chromosomes (14).  Phosphorylation of serine 301 by casein kinase 
II reduces the overall stability of E2 causing it to be targeted for proteosomal 
degradation (59, 146).  HPV-16 E2 has been demonstrated to be modified by the 
small ubiquitin like modifier 1 (SUMO1) protein.  Mutation of the sumoylation site 
on E2, K292, resulted in decreased levels of transcriptional activity (205).  It was 
later shown that increases in overall cell sumoylation levels coincided with 
increase in E2 protein level (204).  This was shown to be through inhibition of 
ubiquitination and thus proteosomal degradation.  The authors hypothesize E2 
will be stabilized in differentiating tissue where host sumoylation levels are 
increased (204).  
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CHAPTER II 
The Role of Histone Acetyltransferase Proteins in BPV-1 E2 Dependent 
Transcriptional Regulation 
 
  
  
25 
 
Introduction 
Acetylation and Histone Acetyltransferase Proteins 
Protein acetylation is one of the most common modifications in eukaryotes.  Co-
translational Nα-terminal acetylation occurs in 85% of eukaryotes with varied 
outcomes (148).  Less common, but more biologically important, is post-
translational acetylation of the ε-amino group of internal lysine side chains.  
Lysine acetylation, which was initially described with respect to acetylation of 
histone tails, was thought to generally increase gene expression (3, 76).  This led 
to the idea that the reduction of the positive charge through lysine acetylation 
decreased the electrostatic interaction between histones and DNA leaving the 
DNA more accessible for transcription factors to bind (97).  The consequences of 
histone acetylation proved to be more complex; subsequent experiments 
demonstrated increases in specific lysine acetylation on histones in regions of 
both transcriptional inactivity and hyperactivity (192).  These results indicated 
that acetylation of specific lysine residues regulated gene expression rather than 
a net reduction of positive charge. 
Further advances were made following identification of histone acetyltransferase 
proteins.  The yeast co-activator Gcn5 was identified as an acetyltransferase in 
1995 following development of an assay to detect acetyltransferase activity (27).  
Subsequently, many known co-activator proteins were found to also encode 
acetyltransferase activity including p300/CBP, the p300/CBP associated factor 
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(pCAF), TAFII250, which is a subunit of the transcriptional initiation factor TFIID, 
and Tip60 (12, 132, 141, 208).  Acetyltransferase proteins are classified into two 
major families based on similarities in their catalytic domains.  MYST (MOZ, 
Ybf2/Sas3, Sas2, and Tip60) family acetyltransferases, which contains Tip60 are 
characterized by their signature MYST domain (184), are reported to be involved 
in long-range/chromosome wide gene regulation.  The GNAT super family 
(Gcn5-related N-AcetylTransferase) of acetyltransferases is characterized by the 
presence, to varying degrees, of four conserved motifs (139); motif A is the most 
conserved and is responsible for acetyl-CoA recognition and binding (47, 203).  
The remaining HATs that do not have common structural motifs, including 
p300/CBP, are grouped into an orphan category (97). 
It was noted early that acetylation of histone substrates appears to be non-
random (33).  Some specificity is directly related to the ability of the HAT’s 
catalytic domain to recognize specific context around acetylated lysines.  
Analysis of the sequence around acetylated lysines of histone tails led to 
development of a two step classification (95).  First, acetylation sites are grouped 
into three classes determined by the residue immediately preceding the lysine.  
Second, each class is further subdivided into two groups determined by 
sequence similarity of the remaining four flanking residues.  The recognition of 
lysines by each HAT is based on the ability of the HAT to recognize a created 
surface around the lysine and not necessarily a specific consensus sequence 
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(95, 97).  This may explain the overlapping but not identical sequence preference 
for p300/CBP and Tip60 (96). 
HATs are generally found in complex with other proteins.  The function of the 
catalytic subunit its substrate specificity may be dependent upon the other 
subunits in the complex.  Some catalytic domains of HATs are unable to 
acetylate substrates unless they are in complex.  Specifically, Gcn5 is unable to 
acetylate histones efficiently in nucleosomal context; however, this is not the 
case in the multi-protein Gcn5 containing complexes such as SAGA and ADA 
(67).  Complex subunits also confer increased specificity.  A model has been 
proposed that builds upon the two step classification outlined above.  While, the 
two step method identifies the potential substrates in vivo based on substrate 
sequence context (95), the allocation model narrows the specificity using 
different complex subunits (95).  Subunits also commonly encode chromatin 
binding domains such as bromodomains or Tudor domains among others.  
These domains recognize acetylated lysine and dimethylated arginine 
respectively (117).  Through the interaction of these domains with modified 
chromatin, acetyltransferase complexes are recruited to specific areas of 
promoter or enhancer regions where its acetyltransferase activity is required.  
The phenomenon of post-translational modification of histones followed by 
interaction of non-histone proteins specifically to the modified regions became 
known as the histone code hypothesis; recent evidence has expanded upon this 
indicating that the code is more like a language (116, 181, 191).  Specific 
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modifications do not simply turn genes on or off; rather, the combinatorial effect 
of multiple modifications in context regulates gene expression.   
In addition to gene regulation through the acetylation of histones, there is 
mounting evidence that acetylation of non-histone proteins including transcription 
factors is equally important.  The discovery that the tumor suppressor p53 is a 
substrate for p300/CBP demonstrated the possibility for acetylation of non-
histone substrates (71).  Subsequent work has identified a number of lysines on 
p53 that are substrates for p300/CBP, pCAF, and Tip60 (104, 183).  Acetylation 
of specific lysines by different HATs has varied effects on p53 biology.  
Acetylation of p53 on six C terminal lysine residues (K370, K372, K373, K381, 
K382 and K386) correlates with increased p53 stability and transcriptional activity 
(51, 104).  Acetylation of K320 on p53 by pCAF favors cell survival by inducing 
p21 mediated cell cycle arrest (101, 104).  In contrast, acetylation of K120 by 
Tip60 promotes apoptosis (183).   
Many other non-histone proteins have been found to be acetylated.  Cellular 
transcription factors, nuclear factors, DNA damage response proteins, and 
structural proteins have all been shown to be acetylated with various effects on 
their DNA binding ability, sub-cellular localization, half-life, or their ability to 
interact with other proteins (63).  Interestingly, several viral proteins have also 
been demonstrated to be regulated by acetylation.  The adenovirus E1a 12s 
protein has been shown to be acetylated by p300/CBP or pCAF on lysine 239, 
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directly adjacent to its C-terminal binding protein (CtBP) interaction motif (214).  
Initially, acetylation of this residue was initially thought to specifically inhibit E1a 
interaction with CtBP (214).  It has subsequently been found that it may do so 
more subtly by destabilizing the molecular interaction surface resulting in a 
reduction in binding affinity not inhibition of interaction (133).  Additionally, 
acetylation of E1a inhibits its interaction with importin-α3 which enriches 
acetylated E1a in the cytosol (126).  SV40 large Tumor antigen (LTag) has been 
shown to be acetylated on lysine 697 by CBP (171).  Acetylation at this site 
which is adjacent to the C-terminal Cdc4 phospho-degron (CPD) resulted in the 
destabilization of LTag (171).   
Papillomavirus E2: Activated Transcription and Repression 
The role of E2 in viral genome replication and episomal maintenance has been 
discussed previously.  Its specific roles in the regulation of viral transcription are 
less well understood.  While the bovine papillomavirus (BPV) early promoter can 
and is activated by cellular factors, transcriptional activation is enhanced through 
expression of the E2 protein.  Transfected E2 increases transcriptional activation 
of BPV promoter elements and artificial reporters containing E2 binding sites in 
enhancer configuration (176, 177).  The BPV-1 LCR has 12 E2 binding sites, four 
of which are upstream of the major early promoter (p89) and are known as E2 
response element 1 (E2RE1) (176).  The full length E2 protein strongly activated 
the promoter through this enhancer element.  E2 can activate other promoters 
within the BPV LCR through nearby E2 binding sites as well.  In contrast, the E2 
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protein is capable of repressing HPV promoters such as those from HPV-16 or 
18 that contain only 4 E2 binding sites (16, 185, 187).  This repression is thought 
to be due steric hindrance caused by the proximity of an E2 binding site to the 
TATA box.  E2 bound to this site inhibits formation of the transcriptional 
preinitiation complex (40, 44, 45).  Residues important for the transcriptional 
activation function of E2 are also required for repression of the early promoter 
(66).  Repression of HPV promoters in cervical carcinoma cell lines result in 
growth arrest and senescence due to reactivation of the p53 and pRB tumor 
suppressor pathways (64, 65, 202).  
The specific mechanisms by which full length E2 activates and represses the 
early promoter have not yet been fully characterized.  E2 does not have intrinsic 
enzymatic activity.  Therefore, it must act through interactions with cellular 
transcription factors, co-activators.  Many groups have reported interactions of 
cellular factors with BPV-1 E2 and a variety of HPV type E2 proteins.  TFIID, and 
TFIIB, Sp1 have been shown to interact with E2 and are critical for enhancement 
of transcription by E2 (152, 158, 209).  A functional interaction with these factors 
indicates a link between basal and E2 activated transcription.  E2 has been 
shown to functionally interact with other cellular factors to regulate transcription.  
Over expression of the cellular replication and DNA damage response factor 
TopBP1 is demonstrated to increase transcription and transient replication in cell 
culture (19).  Later it was reported that depletion of TopBP1 redistributes E2 into 
higher molecular weight nuclear complexes.  The authors claim that TopBP1 
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tethers HPV-16 E2 and the genome to chromatin (43). poly (ADP-ribose) 
polymerase 1 (PARP), which is also involved in DNA damage repair, is shown to 
interact with HPV-18 E2 CTD and enhance its transcriptional activity.  This 
interaction augments the DNA binding of E2 in vitro (114).  
The double bromodomain protein Brd4, which has been shown to be involved in 
genome maintenance (210), is also a critical factor for E2 dependent 
transcription and has been extensively studied in this regard.  Mutants of E2 that 
are incapable of interacting with Brd4 are also transcriptionally defective (167).  
Transient replication of BPV-1 genomes and transcription of BPV-1 reporters 
were diminished in mouse C127 cells transfected with a C-terminal domain 
fragment of Brd4 (88).  This fragment is the E2 binding region and competes with 
full length Brd4 for interaction.  Similar results were demonstrated for HPV-16 E2 
in C33a cells, although in this human cell line CTD expression had no effect on 
replication of an ori containing plasmid (166).  Additionally, siRNA mediated 
depletion of Brd4 and transfection of E2 mutants incapable of interacting with this 
protein resulted in decreased E2 dependent transcriptional activation (166, 167).  
The interaction between E2 and Brd4 appears to stabilize E2 (56, 112, 215).  
This may explain some of the transcriptional deficiency in the absence of Brd4.  
Brd4 is a key factor in the pTEF-b complex which facilitates promoter escape for 
the RNA polymerase II complex (217).  One recent report has indicated that 
disruption of this interaction by E2 may play a role in mediating transcriptional 
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repression (207).  It is not yet clear if pTEF-b plays a role in E2 dependent 
transcriptional activation. 
E2 also has been demonstrated to interact with the SWI/SNF related chromatin 
remodeling ATPase Brm (105).  This interaction is shown to increase E2 activity 
specifically on chromatinized templates and increase loading of E2 onto DNA 
containing E2 binding sites.  Two cellular factors: Tax1BP1 (199) and Gps2 (also 
known as AMF-1) (26), were identified as E2 interacting partners by yeast two-
hybrid screen and both have been demonstrated to enhance transcriptional 
activation in an E2 dependent manner.  Tax1BP1 stabilizes E2 protein level 
which may at least partially contribute to transcriptional enhancement (199).  
However, the enhancement of E2 dependent transcription by Tax1BP1 and the 
enhancement observed following co-transfection of Gps2 is likely related to 
higher order complex formation with the cellular acetyltransferase p300 (145, 
199). 
p300, CBP, and the GNAT family member pCAF have been shown to interact 
directly with E2 from BPV-1, and HPV types 16, 18, 11, and 6b (113, 115, 137, 
145).  These proteins have also been demonstrated to enhance E2 dependent 
transcription (103, 113, 115, 137, 145).  p300, co-expressed with low amounts of 
HPV-16 E2, can enhance transcriptional activity from the HPV-16 promoter, 
which is generally repressed in the presence of E2 (103).  Gps2 strengthens the 
interaction between BPV-1 E2 and p300 and the presence of Gps2 increases the 
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amount of purifiable acetyltransferase activity in co-immunoprecipitations of p300 
with E2 (145).  CBP was demonstrated to interact with the N-terminal 
transactivation domain of HPV-18 E2 via its N-terminal KIX domain, which is also 
the CREB binding region of CBP (115).  Over-expression of the CBP KIX domain 
alone fused to the VP16 activation domain is capable of enhancing E2 
dependent transcription (115).  Finally, pCAF is known to interact with HPV 6b, 
11, 16, and 18 E2 through its N-terminal 390 amino acids (113).  Enhancement 
of E2 dependent transcription by pCAF cooperates with expression of CBP (113).  
Activation in the presence of both HATs is greater than that observed with either 
alone.  The authors suggest that the two synergize and that pCAF acts in a 
pathway distinct CBP to activate transcription through E2 (113).  The 
acetyltransferase domains of CBP and pCAF are required for E2 dependent 
enhancement and acetyltransferase defective mutants of both of these proteins 
are unable to enhance transcription (113, 115). 
The interactions of p300, CBP, and pCAF with E2 and the requirement for 
acetyltransferase activity suggest a role for these proteins in acetylation of 
histones in the early promoter region or E2 acetylation in the regulation of E2 
dependent transcription.  We investigated the requirement of p300, CBP, and 
pCAF for E2 dependent transcription.  Further, we explored the possibility that E2 
is acetylated and the biological significance of such a modification.  We show that 
E2 is acetylated by p300 and that the potential for modification on a conserved 
N-terminal lysine correlates with transcriptional activation and retention of E2 in 
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the nucleus.  These data present evidence for the direct acetylation of E2 as a 
novel method of regulating its transcriptional activity. 
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Materials and Methods 
Antibodies Primary antibodies used for immunofluorescence, immunoblot, and 
immunoprecipitation include: BPV-1 E2 B201, Santa Cruz p300 N-15 (sc-583), 
CBP A-22 (sc-369), pCAF E-8 (sc-13124), Cell Signaling Technology acetyl-
lysine (9441) and Sigma Aldrich Actin (A-2668).  Secondary antibodies for 
immunofluorescence include Alexafluor 488 and 555 (Invitrogen), and for 
immunoblot include horseradish peroxidase conjugates (Jackson Labs). 
Cells and Transfections RPE-1 cells were cultured in a 1:1 mix of Dulbecco’s 
Modified Eagle Medium (DMEM) and Ham’s F12 Medium (Invitrogen).  RKO 
cells, C127, ID13 cells, and C127-A3 were cultured in DMEM (Invitrogen).  ID13 
and C127-A3 are both transformed with BPV-1 genomes, the latter containing 
three mutations within the E2 reading frame leading to increased E2 protein level 
(119).  All cell culture medium was supplemented with penicillin/streptomycin 
solution (Invitrogen) as well as 10% fetal bovine serum (Atlas Biologicals).  
Transfections were performed using Lipofectamine 2000 transfection reagent 
(Invitrogen) according to manufacturer’s specifications.  All DNA, siRNA, and 
transfection reagents were diluted in Optimem serum free medium (Invitrogen) in 
the absence of antibiotic.   
Chromatin Immunoprecipitation Cells were plated onto 10cm culture dishes, 
for endogenous immunoprecipitation, cells were prepared the following day for 
chromatin immunoprecipitation (ChIP) according to protocol (Upstate Cell 
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Signaling/Millipore), otherwise cells were transfected the following day and 
prepared for ChIP 24 hours post transfection.  Briefly, cells were cross-linked 
with 1% Formaldehyde (Sigma Aldrich) for 10 minutes at 37oC.  Cross-linked 
cells were then lysed in 1% SDS.  Lysates were disrupted using a Branson S-
450D sonifier equipped with a microtip probe.  Lysates were subjected to five, 
five second pulses at 30% amplitude alternated with 30 second rests.  Following 
sonication, lysates were diluted to 0.1% SDS and aliquoted for 
immunoprecipitation with several antibodies.  1% of the original lysate was 
reserved for input.  Antibodies were captured using magnetic Dynabeads 
(Invitrogen).  Following successive washes with Low salt wash buffer (0.1% SDS, 
1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 150mM NaCl), high salt 
wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 
500mM NaCl), LiCl wash buffer (0.25M LiCl, 1% NP-40, 1% deoxycholic acid, 
1mM EDTA, 10mM Tris-HCl pH 8.0), and TE (10mM Tris-HCl pH 8.0, 1mM 
EDTA), DNA-protein complexes were eluted from beads using 1% SDS and 
cross-links were reversed by adding NaCl to a final concentration of 0.2M and 
heating samples to 65oC for no less than four hours.  DNA was then purified 
using QIAquick PCR purification kit (QIAGEN) according to the manufacturer’s 
protocol.  Purified samples were amplified by PCR using BPV-1 LCR primers 
(Table 2.1) and separated on 1% agarose gel.    
Immunofluorescence Cells were plated on collagen coated coverslips (BD 
Biosciences) and transfected the following day with expression plasmids.  24  
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Table 2.1 RNA and DNA Oligonucleotide Sequences 
 
  
Type Name Sequence Purpose 
siRNA Human p300 CAGAGCAGUCCUGGAUUAG Depletion 
siRNA Mouse p300 Ambion Catalog # s116226 Depletion 
siRNA Human CBP AAUCCACAGUACCGAGAAAUG Depletion 
siRNA Mouse CBP Ambion Catalog # s64378 Depletion 
siRNA Human/Mouse pCAF UCGCCGUGAAGAAAGCGCA Depletion 
DNA BPV-1 LCR Sense AAAGTTTCCATTGCGTCTGG ChIP 
DNA BPV-1 LCR Antisense GCTTTTTATAGTTAGCTGGCTATTTT ChIP 
DNA BPV-1 E6 Sense ATGGACCTGAAACCTTTTGC QPCR 
DNA BPV-1 E6 Antisense CAGCCTTCCCGAATTACAAC QPCR 
DNA BPV-1 E2 Sense AGGCTGGGGCTGACGGAACT RTPCR 
DNA BPV-1 E2 Antisense GCTCTGATGGGACCGCAGGC RTPCR 
DNA p300 Sense CTTTTACATGCTCACAAGTGCCAGC RTPCR 
DNA p300 Antisense GCTAGGGTTTCCAAGCCCAACT RTPCR 
DNA CBP Sense TCCCAAGCACTGAATCCACAAGCA RTPCR 
DNA CBP Antisense TCAAGGTCTCCGCCAGCACA RTPCR 
DNA pCAF Sense GAAGGCGCAGTTGCGCTCTGCT RTPCR 
DNA pCAF Antisense GCAAGGGCATGGCTACAGCTTCGAC RTPCR 
DNA Beta Actin Sense GGGAAATCGTGCGTGACATTAAG QPCR 
DNA Beta Actin Antisense TGTGTTGGCGTACAGGTCTTTG QPCR 
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hours after transfection, cells were fixed using 3.7% paraformaldehyde (Electron 
Microscopy Sciences) diluted with phosphate buffered saline (PBS) for 30 
minutes, and permeabilized using 0.2% Triton X-100 diluted with PBS for 10 
minutes.  Cells were then blocked overnight in 5% normal goat serum 
(Invitrogen), 1% bovine serum albumin (BSA), and 0.05% Triton X-100 in PBS 
and then incubated for one hour each with primary and then secondary 
antibodies diluted in blocking buffer.  Coverslips were washed three times with 
0.05% Triton X-100 in PBS following both primary and secondary antibody 
incubations.  Coverslips were mounted on glass slides using ProLong Gold 
antifade reagent with 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen).  Cells 
were then visualized and images were collected using a Leica TSC SP2 AOBS 
confocal microscope using Leica Imaging Software.   
Immunoprecipitation and Immunoblot RPE-1 cells were plated on 10 cm 
tissue culture dishes.  The following day cells were transfected with a 
combination of pCG vector, E2, or Gps2s.  24 hours post transfection, cells were 
harvested by rinsing with phosphate buffered saline (PBS), scraping into a small 
volume of PBS for transfer to an Eppendorf tube.  Cells were lysed using IPLB 
(50mM Tris-HCl pH 8.0, 0.1mM NaCl, 20mM NaF, 10mM KH2PO4, 1% Triton X-
100, 10% Glycerol, 0.1mM DTT, 2mM PMSF, and Complete protease inhibitor 
cocktail Roche).  Lysates were clarified by centrifugation at 15,000 x g for ten 
minutes. Lysates were the diluted 1:1 with IPBB (50mM Tris-HCl pH 8.0, 0.1mM 
KCl, 0.1mM EDTA, 0.2% NP-40, 0.5 µg BSA, 2.5% Glycerol, 0.1mM DTT, 2mM 
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PMSF), specific antibodies were added and complexes were formed with gentle 
agitation overnight at 4oC.  Protein A or Protein G sepharose beads (Invitrogen) 
were added the following day and complexes were collected for 1 hour.  After 
extensive washing with IPWB (0.1mM Tris-HCl pH 8.0, 0.1mM NaCl, 0.2% NP-
40, 0.1mM DTT, 2mM PMSF) complexes were separated by SDS-
Polyacrylamide Gel Electrophoresis (PAGE) and membranes were probed for 
target proteins.  For each individual lysate, 5% of the total volume used for each 
immunoprecipitation used was reserved for use as input protein.  This sample 
was separated by SDS-PAGE with the immunoprecipitated complexes for 
reference of protein expression. 
Cells for immunoblot analysis were plated onto six-well dishes, transfected the 
following day with either expression plasmid or expression plasmid and siRNA.  
24 hours following transfection, or 48 hours following siRNA transfection, cells 
were lysed using 2% SDS in 50mM Tris-HCl pH 8.0 and 1mM dithiothreitol 
(DTT).  Lysates were then homogenized by passing through a QIAshredder spin 
column (QIAGEN) and protein concentration was estimated using BCA protein 
assay (Thermo Scientific).  Equal amounts of protein were loaded and separated 
by SDS-PAGE.  Gels were transferred to polyvinylidene fluoride (PVDF) 
membrane (Millipore), blocked and then probed with specific antibodies. Signal 
was detected by chemiluminescence (Thermo Scientific).   
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In Vitro Acetylation Assay 200ng of protein substrate was mixed with 50ng of 
acetyltransferase in a 10 µL reaction containing 40mM Tris-HCl pH 8.0, 75mM 
potassium chloride (KCl), and 10 µM Acetyl CoA (Sigma Aldrich).  Each reaction 
was held a 30oC for one hour and stopped by the addition of SDS-PAGE sample 
buffer and increasing the temperature to 95oC for five minutes.  Proteins were 
then resolved by SDS-PAGE, transferred to PVDF membrane, and probed for 
acetylated substrates using an anti acetyl-lysine antibody (Cell Signaling 
Technology).  Duplicate samples were stained for total protein using Coomassie 
Brilliant Blue R250 (Fischer).  Substrates tested included BPV-1 E2, p53, and 
histone protein purified from HeLa cells, acetyltransferases included p300, pCAF, 
and Gcn5.  Gcn5, p53, and BPV-1 E2 were purified from bacteria, pCAF and 
p300 were purified from baculovirus infected Sf9 cells, and histone proteins were 
purified from HeLa cells.  
Luciferase Reporter Assay Cells were plated onto six-well dishes and 
transfected in triplicate the following day with luciferase reporter, expression 
plasmids, and siRNA.  Cells were lysed 24 hours after transfection or 48 hours 
after siRNA transfection by directly applying Reporter Lysis Buffer (Promega) to 
each well and submitting lysates to one freeze thaw cycle.  30 µL of each lysate 
was added into duplicate wells of a CulturPlate-96 (Perkin Elmer).  100 µL of 
Luciferase Assay Reagent (Promega) was added to each well just prior to 
reading on an EnVision Multilabel Plate Reader (Perkin Elmer).  Data was 
averaged from duplicate wells and means were calculated from each 
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experimental triplicate.  Means were averaged from at least 4 independent 
experiments and error bars represent the standard error of the mean (SEM).  
Wild type E2 transcriptional activation in the presence or absence of control 
siRNA was set at 100% and each experimental value was calculated as a 
percentage of wild type or control.  One-way ANOVA with either Dunnet’s or 
Bonferroni’s post-hoc analysis was performed with GraphPad Prism version 5.01 
for Windows. 
Mass Spectrometry and Data Analysis BPV-1 E2, acetylated in vitro, was 
resolved by SDS-PAGE and the gel was then stained with Coomassie Brilliant 
Blue R250 (Fischer).  The band corresponding to BPV-1 E2 was excised, de-
stained and prepared for digestion.  The band was then split and digested with 
trypsin, chymotrypsin, or GluC overnight at 30oC.  Peptides from each sample 
were injected using a NanoAquity Auto Sampler (Waters, Inc.) onto a Symmetry 
C18 trapping cartridge (Waters, Inc.).  Peptides were separated by in-line 
gradient elution onto a 75 µm internal diameter × 10 cm column packed with BEH 
130 stationary phase (Waters Inc), using a linear gradient from 3% to 90% 
solvent B where A= 2% acetonitrile and B= 98% acetonitrile both containing 0.1% 
formic acid and 0.01% trifluoroacetic acid.  During the gradient elution, data 
dependant scans were performed with 8 scan events per cycle consisting of one 
full MS from m/z 400 – 2,000 followed by product ion scans (collision induced 
dissociation=  35%) on the 10 most intense ions in the full scan.  Precursor ions 
used for product ion scans were dynamically excluded for 30 seconds.  Proteins 
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were identified from the product ion spectra using the SEQUEST (Thermo 
Scientific) and X!Tandem search engine across the entire Swiss-Prot database 
(7), the results from each search were combined using Scaffold v3.00 (Proteome 
Software, Portland, Oregon, USA).  
Plasmids and siRNAs pGL2-E24BS contains 4 E2 binding sites up stream of an 
SV40 promoter which drives luciferase expression.  Expression plasmids used 
include pCG-E2, pCMV β-p300, pRSV-CBP, and pCI-pCAF.  All E2 lysine to 
arginine mutants were generated with the Quickchange II site directed 
mutagenesis system (Agilent Technologies) using pCG-E2 as a template. ∆Nco1 
BPV-1 genome does not express E2 resulting from a deletion within the E2 
reading frame (143). siRNAs directed toward p300, CBP, and pCAF were 
purchased from Ambion (mouse p300 and CBP catalog numbers s116226 and 
s64378, all other siRNAs were custom designed. Sequences are presented in 
table 2.1). 
Quantitative Real-time PCR and RT-PCR Purified DNA for quantification of 
ChIP assay was added in triplicate to wells of an iQ 96-well real time PCR plate 
(Bio-Rad) and amplified using a Mastercycler ep realplex thermal cycler 
(Eppendorf) with BPV-1 LCR primers listed above.  A four point, tenfold dilution 
series was prepared from input DNA of each individual lysate for a reference 
curve.  Ct values of each immunoprecipitated DNA sample were then compared 
to the appropriate reference curves and calculated as a percentage of input DNA.  
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RNA for analysis of gene expression was purified by RNeasy kit (QIAGEN).  
RNA was then reverse transcribed using ImProm-II reverse transcription system 
(Promega).  cDNA was added in triplicate to wells of an iQ 96-well real time PCR 
plate (Bio-Rad) and amplified using a Mastercycler ep realplex thermal cycler 
(Eppendorf) with E6 and beta actin primers (Table 2.1).  Primer efficiencies were 
obtained by performing a standard curve titration and then used to relate the Ct 
values by the Pfaffl method.  Two-way ANOVA was performed with Bonferroni’s 
pos-hoc analysis using GraphPad Prism version 5.01 for Windows.  Depletion of 
each HAT was confirmed by performing RT-PCR analysis on identical template 
cDNA using oligos listed in table 2.1.   
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Results 
p300, CBP, and pCAF are Necessary for E2 Dependent Transcription 
Over expression of histone acetyltransferase (HAT) proteins, specifically p300, 
CBP, and pCAF, has been reported to enhance E2 dependent transcription (113, 
115, 137, 145); however, little is known of the biochemical consequences of 
these protein interactions, and specifically how these proteins affect E2 
dependent transcription.  To characterize the role of HATs in transcription, E2 
responsive luciferase reporter plasmids were co-transfected with BPV-1 E2 and 
either control siRNA or siRNA targeting p300, CBP, or pCAF.  Activation of the 
reporter by E2 in the presence of control siRNA was nearly 80 fold greater than 
in the absence of E2, which is consistent with previous reports (26).  siRNA 
mediated depletion of either p300 or CBP resulted in approximately 50% 
reduction of reporter activity compared to cells transfected with control siRNA 
(Fig 2.1a).  Similarly, depletion of pCAF resulted in an approximate 40% 
reduction of reporter activity (Fig 2.1a).  Protein depletion was confirmed by 
immunoblot analysis and a 50% or greater reduction in protein level was 
observed for each protein in the presence of corresponding siRNA (Fig 2.1b).  
p300, CBP, and pCAF are general transcriptional cofactors; as a result, depletion 
of these proteins may result in unforeseen consequences on transcription from 
the E2 expression construct.  To address this concern, E2 protein level was 
examined in the context of each siRNA transfected and determined to be 
unaffected (Fig 2.1b and c).  Significant decreases in reporter activation following 
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 Figure 2.1 p300, CBP, and pCAF are independently necessary for E2 
dependent transcription.  A RPE-1 cells were transfected with a 
luciferase reporter plasmid containing 4 E2 binding sites, E2, and 
control siRNA or siRNA directed toward p300, CBP, or pCAF.  
Luciferase activity was detected 48 hours post transfection.  
Results are presented as a percentage of control.  One way 
ANOVA was performed with Dunnet’s post-hoc analysis 
comparing knockdown to control, ** p<0.01 and *** p<0.001.  B 
Lysates from transfected cells were prepared for SDS-PAGE and 
immunoblot analysis was performed to confirm protein depletion.  
C Quantitation of E2 protein level present in B.  Band intensities 
were measured and compared to those of actin. Data is presented 
as a percentage of E2 protein level present in control siRNA 
transfected cells. 
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depletion of p300, CBP, and pCAF suggest that each protein is necessary for E2 
dependent transcription.  While analysis of synthetic reporter activation is 
informative in revealing the possibility that HATs may be necessary for E2 
dependent transcription, this is an idealized situation with four high affinity E2 
binding sites upstream of an active promoter.  In order to extend these 
experiments to a physiological setting, the effect of HAT depletion was 
determined on the expression of the BPV-1 E6 oncoprotein from the viral early 
promoter.  Depletion of p300, CBP, and pCAF, all resulted in at least a 50% 
reduction in E6 RNA expression as compared to control siRNA transfection (Fig 
2.2a).  These results are consistent with those observed in the luciferase reporter 
assay.  The drawback of this particular experiment is that while physiological, the 
role of E2 cannot be determined.  To examine this, a mutant genome must be 
employed that does not express E2.  Then the level of E6 expression may be 
measured after introduction of E2 and compared to that following HAT depletion.  
In this assay, p300, CBP, and pCAF were amplified by conventional PCR to 
determine the extent of siRNA mediated knockdown.  While pCAF transcript 
levels were nearly undetectable following siRNA transfection, depletion of p300 
and CBP resulted in approximately 50% reduction in transcript (Fig 2.2b).  The 
difference in knockdown efficiency may be attributable to as different set of 
siRNAs used in this experiment.  ID13 cells are of mouse origin, the p300 and 
CBP siRNAs used in the luciferase reporter assay were directed toward a non-
homologous region of the human proteins.  The siRNA recognizing pCAF was  
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 Figure 2.2 p300, CBP, and pCAF are necessary for E2 dependent 
genomic transcription.  A ID13 cells were transfected with a 
control siRNA or siRNA directed toward p300, CBP, or pCAF.  
RNA was isolated 48 hours post transfection and E6 mRNA levels 
were measured by real-time PCR.  Results are presented as a fold 
change compared to control transfection. Error bars are not 
included because data is preliminary and the experiment was only 
performed twice.  B HAT mRNA was amplified from RNA isolated 
from siRNA transfected lysates.  Intensity of each band was 
measured and normalized to beta actin.  Each bar represents the 
mRNA expression level of the protein being depleted as a 
percentage of levels of that mRNA following control siRNA 
transfection. 
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identical to that used in the luciferase assay. 
The finding that p300, CBP, and pCAF are each limiting was surprising as there 
is a large overlap in substrate range for many HATs and particularly for p300 and 
CBP, which are highly homologous and similar in function (130, 162).  The 
possibility that there is functional redundancy between these proteins was 
explored by examining the ability of one HAT to restore reporter activation in the 
context of depletion of another HAT protein.  CBP and pCAF were unable to 
significantly increase transcriptional activation in the context of p300 depletion in 
RPE-1 cells (Fig 2.3a).  This indicates neither CBP nor pCAF can replace the 
activity of p300 with respect to E2 dependent transcriptional activation.  Similarly, 
neither p300 nor pCAF could replace the transcription activity of CBP and neither 
p300 nor CBP could replace the transcriptional activity of pCAF (Fig 2.3a).  
Confirmation of HAT depletion as well as overexpression is presented in figure 
2.3b. 
The Co-Activator Gps2 Increases Immunoprecipitation with HATs 
Gps2 has previously been demonstrated to interact both with E2 and p300 (145).  
Gps2 facilitates the interaction between p300 and E2 as evidenced by the 
increase in HAT activity in lysates precipitated with E2 antibodies in the presence 
of this protein (145).  Given the importance of the HATs pCAF and CBP in E2 
dependent transcriptional activation, we sought to determine if Gps2 plays a role 
in these complexes as well.  E2 was co-precipitated in increasing abundance by  
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Figure 2.3 p300, CBP, and pCAF function independently in E2 dependent 
transcription.  A RPE-1 cells were transfected with a luciferase 
reporter plasmid containing 4 E2 binding sites, E2, and p300, 
CBP, or pCAF were expressed in the presence of siRNA directed 
toward p300, CBP, or pCAF.  Each graph represents one 
transfected siRNA and results are presented as a percentage of 
activation in the presence of control siRNA.   One way ANOVA 
was performed with Dunnet’s post-hoc analysis comparing each 
overexpressed protein to vector alone.  All comparisons are 
statistically insignificant.  B Lysates from transfected cells were 
prepared for SDS-PAGE and immunoblot analysis was performed 
to confirm protein depletion and overexpression.  
 A 
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transfection of Gps2, co-precipitation of E2 by p300 was increased (Fig 2.4).  
pCAF also co-precipitated a greater amount of E2 following Gps2 expression.  
Conversely, expression of Gps2 did not appear to have any effect on the co-
precipitation of E2 with CBP (Fig 2.4).  Gps2 is known to exist in a co-repressor 
complex in addition to interacting with p300 (213).  While this may result in 
changes in levels of basal transcription, this would not account for increases in 
association of HATs and E2.  Transfection of Gps2 does not affect levels of E2 
expression.  
p300 and CBP but Not pCAF Interact with the BPV-1 Genome 
A previous report has demonstrated that pCAF increases the amount of 
acetylated histone on a luciferase reporter (113).  This may indicate that E2 
recruits acetyltransferase proteins to the early promoter to modify chromatin.  
This report does not directly examine the presence of HAT on the promoter.  
Here, we address this through chromatin immunoprecipitation (ChIP) of 
endogenous HAT on episomally maintained BPV-1 genomes.  Compared to 
control immunoprecipitation (IP) and IP in C127 cells, which do not contain BPV-
1 genomes, E2 was detected on BPV-1 genomes in ID13 cells (Fig 2.5a).  p300 
and CBP IP also led to co-precipitation of genomes (Fig 2.5a).  Conversely, IP 
using a pCAF antibody failed to co-precipitate BPV-1 genomes in ID13 cells (Fig 
2.5a).  The antibody used to IP pCAF in figure 2.5a is the same used in the IP 
shown in figure 2.4 and all immunoblots for pCAF.  These proteins exhibit similar 
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 Figure 2.4 Gps2 facilitates complex formation between E2 and HATs.  
RPE-1 cells were co-transfected with E2 and either empty vector 
or Gps2.  Cells were lysed and lysates divided for co-
immunoprecipitation with endogenous HAT protein.  Antibodies 
used for immunoprecipitation are indicated above the top panel.  
Precipitates were probed for E2 using B201 antibody.  The bottom 
left panel represents each lysate precipitated with control IgG 
antibody and the bottom right panel represents 5% of the total 
lysate added to the immunoprecipitation reaction and * indicates a 
background band present in the B201 E2 immunoblot. 
  
Figure 2.4Gps2 facilitates complex formation between E2 and HATs.
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Figure 2.5 p300 and CBP but not pCAF interact with the BPV1 genome.  
A Untransfected C127, ID13, and C127-A3 lysates were prepared 
for ChIP assay and immunoprecipitated using either control 
antibody, or antibodies recognizing BPV1 E2, p300, CBP, or pCAF.  
Precipitated DNA was amplified by PCR.  B C127 cells were 
transfected with ∆Nco1 genomes in the presence or absence of 
BPV1 E2.  Lysates were prepared for ChIP assay and 
immunoprecipitated using control antibody, or antibodies directed 
at BPV1 E2 (B201), p300, CBP, or pCAF.  Precipitated DNA was 
quantified using real time PCR.  Two-way ANOVA with 
Bonferonni’s post-hoc analysis was performed comparing genome 
alone and genome plus E2 for each individual IP, * p<0.5, *** 
p<0.001. 
  
Figure 2.5 p300 and CBP but not pCAF interact with the BPV1 genome.
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binding patterns in C127-A3 cells.  E2 IP co-precipitates the genome, as does 
p300 and CBP IP; however, pCAF is still unable to precipitate BPV genomes in 
C127-A3 cells (Fig 2.5a).  
While it is difficult to specifically determine the amount of genome precipitated in 
each sample, it appears that CBP co-precipitates more genome in C127-A3 cells 
than ID13 cells (Fig 2.5a).  The difference between these two cell lines is a series 
of serine to alanine mutations in the E2 reading frame that results in higher E2 
protein levels in the cell (119).  We next asked if E2 specifically recruits either 
p300 or CBP to the BPV-1 genome.  C127 cells were transfected with ∆Nco1 
genomes with or without co-transfected E2.  These genomes do not express E2 
and allow exogenous complementation.  Compared to control IgG IP, both p300 
and CBP were found on the genome in the absence of E2 (Fig 2.5b).  Following 
transfection of E2, a dramatic increase in genome bound E2 was observed as 
expected (Fig 2.5b).  Interestingly, there was also an increase in the amount of 
genome bound CBP in E2 transfected samples (Fig 2.5b).  This increase which 
was nearly two fold was statistically significant (p<0.05).  p300 was detectable 
following expression of E2; however, no significant increase was detected and 
pCAF levels were below those of IgG control IP in the presence and absence of 
E2 (Fig 2.5b).  While it appears that different levels of each of genome are 
precipitated by each antibody in the presence or absence of E2, this may not 
truly be the case.  It is difficult to compare IP between different antibodies given 
varying affinities for each cognate antigen.  In this experiment one may only 
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compare samples in the presence or absence of E2 for each individual antibody.  
In order to compare between antibodies, an antibody titration must be performed 
to determine the relative affinities of each antibody, then the one may normalize 
to ensure equal precipitation of each protein and compare the relative 
abundances of genome precipitated. 
E2 Interaction with DNA is Facilitated by p300 
We have now identified at least two HATs that form complexes with the BPV-1 
genome.  We have presented evidence that suggests CBP may complex with E2 
on the genome; it is also possible that p300 is in complex with E2 on the genome 
as well.  We next asked if the critical E2 transcriptional co-factor and acetyl-
histone interacting protein Brd4 was recruited into complexes with HATs and E2.  
Using ID13 cells we transfected control siRNA or that directed toward p300, 
CBP, or pCAF.  We then used quantitative ChIP assay to determine the amount 
of Brd4 was bound to the LCR.  Both E2 and Brd4 were both found to be present 
on the LCR in after control siRNA transfection (Fig 2.6).  Following depletion of 
p300 we observed a 50% reduction in LCR interaction for both Brd4 and E2 (Fig 
2.6).  Depletion of CBP did not result in a decrease in occupancy for either 
protein.  Interestingly, depletion of pCAF did not affect the interaction of E2 to the 
genome; however, it resulted in an increase of nearly 2 fold for Brd4 (Fig 2.6).  
Depletion of HAT protein for this experiment is consistent with that seen in figure 
2.2. 
60 
 
  
 Figure 2.6 p300 facilitates the interaction of E2 and Brd4 to DNA. ID13 
cells were transfected with either control siRNA or siRNA directed 
toward p300, CBP, or pCAF.  48 hours post transfection, cells 
were crosslinked and immunoprecipitated with control IgG or 
antibodies to E2 or Brd4.  The amount of bound DNA was 
quantified by real-time PCR.  Data is presented as a percentage of 
input DNA from each precipitated lysate.  Statistics are omitted 
due to the low number of replicates. 
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E2 and Brd4 Bound to BPV-1 Genome 
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E2 is Acetylated by p300  
Previous studies evaluating the interactions of HATs p300, CBP, and pCAF with 
BPV-1 E2 have primarily focused on the effects of HAT over expression on 
transcriptional activation.  While these reports provide evidence that HATs affect 
E2 dependent transcription, little is known about the mechanism.  Despite 
evidence that acetyltransferase activity is necessary for enhancement by CBP 
and pCAF (113, 115), acetylation of E2 has not been reported.  We attempted to 
detect acetylation of E2 in RPE-1 cells.  Acetylated E2 was not detected in mock 
transfected cells or cells transfected with E2 alone.  However, upon over-
expression of either p300 or CBP, we were able to detect a band migrating just 
above the 50 kDa marker (visible in first and last lanes) (Fig 2.7).  We were not 
able to detect acetylated E2 following expression of pCAF in these cells.  
Acetylated endogenous p53 was detectable in all lanes (Fig 2.7 middle panel) 
and no visible bands were detected in a control immunoprecipitation (Fig 2.7 
lower panel).  Although we were able to detect acetylated E2 in RPE-1 cells, 
these experiments were inconsistent and subsequent attempts to purify 
acetylated BPV-1 E2 transfected in RPE-1 cells, in ID13 cells which express E2 
from episomally maintained BPV-1 genomes, and in RKO cells transfected with 
FLAG tagged E2 were unsuccessful (data not shown).  These experiments were 
likely unsuccessful due to limitations of new lots of anti-acetyl lysine antibodies 
used for detection and the possibility of interfering factors in vivo. Here, we 
perform in vitro acetylation reactions where each protein was expressed and then 
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 Figure 2.7 E2 is acetylated by p300 and CBP.  RPE-1 cells were 
transfected with empty vector, E2 alone or E2 co-transfected with 
p300, CBP, or pCAF.  Cells were treated with trichostatin A for 12 
hours and lysed 24 hours post transfection.  Lysates were 
immunoprecipitated with control antibody or antibodies directed to 
E2 or p53.  Precipitated protein was separated by SDS-PAGE and 
probed with an anti-acetyl lysine antibody.  Each panel represent a 
separate immunoprecipitation. 
  
Figure 2.7 E2 is acetylated by p300 and CBP.
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purified from either bacteria or baculovirus infected Sf9 cells. Purified HAT and 
E2 proteins were mixed in the presence of acetyl CoA and resulting acetylated 
E2 was then detected by immunoblot analysis with an acetyl lysine antibody.  
Histone protein and p53 were used as positive controls for acetylation by p300, 
pCAF, and Gcn5.  We were unable to obtain purified CBP protein at the time of 
these experiments.  Robust acetylation was detected on histone substrates with 
all of the HATs (Fig 2.8a).  p300 mediated strong acetylation of p53 while pCAF 
and Gcn5 were less active (Fig 2.8a).  This may reflect that p300 acetylates p53 
on several more lysines than does pCAF or Gcn5 (13, 150) or peptide epitope 
preference.  When BPV-1 E2 was incubated with p300, a strong band 
corresponding to acetylated E2 was observed.  Acetylation of E2 was not 
detected by immunoblot following incubation with either Gcn5 or pCAF (Fig 2.8a).   
E2 lysines specifically targeted by p300 were identified using a proteomic 
approach. BPV-1 E2 was acetylated in vitro, digested, and the resulting peptides 
were analyzed by mass spectrometry for lysine acetylation.  Each peptide was 
compared to the entire Swiss-Prot database and assembled using both the 
SEQUEST and X!Tandem search engines.  These two utilities directly compare 
uninterpreted tandem mass spectra to protein databases, using different 
algorithms, resulting in protein identification.  Digestion of BPV-1 E2 with trypsin 
yielded no acetylated peptides, likely attributed to the inability of trypsin to cleave 
after acetylated lysines. Analysis of chymotrypsin digestion yielded 97% total 
sequence coverage and identified eleven acetylated lysine residues on BPV-1 E2 
66 
 
  
Figure 2.8 E2 is acetylated by p300 in vitro.  A In vitro acetylation of purified 
histone protein (Top left), p53 (Bottom left), and BPV-1 E2 (Top 
Right), using purified acetyltransferases p300, pCAF, and Gcn5.  
Acetylation is detected by immunoblot using an anti acetyl-lysine 
antibody.  The higher molecular weight band (*) visible in p53 and 
BPV-1 E2 acetylation by Gcn5 is due to auto-acetylation of 
truncated Gcn5.  Input for each substrate as well as each 
acetyltransferase (bottom right) is presented as a duplicate 
reaction processed in parallel for which the gel was stained for 
total protein using coomassie brilliant blue.  B Acetylated peptide 
sequence coverage of BPV-1 E2 obtained from mass 
spectrometry.  Sequence identified in samples digested with 
chymotrypsin are underlined and those identified with gluC are 
highlighted yellow.  Detected acetylated lysine residues are in red. 
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Figure 2.8 E2 is acetylated by p300 in vitro.
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(Fig 2.8b).  Analysis of GluC digestion yielded 89% sequence coverage and nine 
acetylated lysines, of which three were unique to GluC digestion (Fig 2.8b).  In 
total, 14 of 16 lysines encoded in BPV-1 E2 were found to be acetylated in vitro.  
Nine lysines are in the N-terminal transactivation domain, five in the C-terminal 
DNA binding domain, and one in the central hinge region.  Acetylated lysines 
were discovered in an average of 22% of each unique E2 peptide identified.  The 
frequency with which each lysine was found to be acetylated ranged from 3% to 
60% of the total pool of each unique peptide identified.  The low average 
frequency of acetylation (22%) could explain the difficulty detecting acetylated E2 
in mammalian cell culture.  A summary of data compiled from chymotrypsin and 
GluC digests including SEQUEST and X!Tandem correlation scores is presented 
in Table 2.2. 
E2 Lysine Mutations Display Transcriptional Defects 
We next sought to investigate the significance of E2 acetylation by p300 in vivo. 
Six identified lysines were selected for mutation on the basis of sequence 
conservation in BPV-1 and several HPV types, frequency with which the modified 
lysine was identified in proteomic analysis, and SEQUEST and X!Tandem 
correlation scores.  Lysines 107, 111 and 112 are part of a reported BPV-1 E2 N-
terminal nuclear localization signal (NLS) (172), lysines 111 and 112 are 
conserved throughout eight HPV types including high risk types 16, 18, and 31 
(Fig 2.9a), and lysine 339 is a critical residue that mediates interaction with E2 
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Table 2.2 Proteomic Analysis of Acetylated E2 
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21 0.94 - 4 12 33% 
25 0.9 - 4 11 36% 
70 0.99 2.07 3 13 23% 
84 0.53 2.49 3 11 27% 
107 1.2 3.19 6 31 19% 
111 0.94 3.12 5 29 17% 
112 1.2 3.19 6 29 21% 
149 0.36 - 1 30 3% 
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 322 0.39 3.5 4 14 29% 
339 0.79 4.09 5 23 22% 
346 2.38 - 3 5 60% 
347 0.31 - 1 5 20% 
391 1.56 2.46 8 24 33% 
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 Figure 2.9 E2 lysine to arginine mutants exhibit transcriptional 
abnormalities.  A Sequence alignment around amino acids 106 to 
119 of BPV-1 E2.  Alignment was prepared using ClustalW 
multiple alignment tool. B RPE-1 cells were co-transfected with an 
E2 responsive luciferase reporter and either wild type E2 or one of 
a series of lysine to arginine mutants.  Luciferase activity was 
detected 24 hours post transfection and results are presented as a 
percentage of wild type E2 activation.  One way ANOVA was 
performed with Dunnet’s post hoc analysis comparing each mutant 
to wild type E2, * p<0.05, ** p<0.01, *** p<0.001.  C Lysates of wild 
type and mutant E2 transfected RPE-1 cells were prepared for 
SDS-PAGE and immunoblot analysis was performed to determine 
the steady state protein level of each E2 expression construct.  A 
longer exposure was required to detect E2 K111R and E2 
K111R/K112R (Bottom panel). D mRNA from RPE-1 cells 
transfected with E2 mutants was reverse transcribed and amplified 
by using E2 or beta-actin primers. 
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Figure 2.9 E2 lysine to arginine 
mutants exhibit transcriptional 
abnormalities. 
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DNA binding sites (149).  Lysines were mutated to arginine to avoid effects 
related to charge and protein folding. Each mutant was screened for its ability to 
activate transcription from an E2 responsive reporter and for protein levels. 
E2 mutants K70R and K391R activated transcription to levels equal to those 
observed for wild type E2 (Fig 2.9b) despite protein levels approximately 70% of 
wild type (Fig 2.9c).  The K107R E2 mutant protein was present at higher levels 
than K70R and K391R, 85% of wild type level (Fig 2.9c); however, this mutant 
was observed to be slightly deficient for transcriptional activation (Fig 2.9b).  The 
K339R E2 mutant was moderately impaired in its ability to activate transcription 
(Fig 2.9b).  This may be partially attributable to decreased protein levels 
compared to wild type E2, however increasing amounts of K339R mutant 
transfection resulted in a peak of transcriptional activity at less than 50% of that 
observed for wild type E2 (Fig 2.10).  K111R, K112R, and a double mutation 
including both residues were expressed to levels between 27% and 40% of wild 
type levels (Fig 2.9c).  Despite its diminished protein level, the K112R E2 mutant 
activates transcription to levels two fold higher than those observed for wild type 
E2 (Fig 2.9b).  In contrast to K112R, the K111R and K111R/K112R mutants were 
both impaired in their ability to activate transcription (Fig 2.9b).  The expression 
level of K111R was only partially responsible for the transcriptional deficiency.  
Transfection of increasing amounts of K111R resulted in a maximum of 60% of 
wild type activity (Fig 2.10). This was not the case for the K111R/K112R mutant 
where increasing transfection did not restore any transcriptional activity (Fig  
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 Figure 2.10 Transcriptional dose response for E2 K/R mutants.  A RPE-1 
cells were transfected with a luciferase reporter plasmid 
containing 4 E2 binding sites, and either 75ng, 150ng 300ng or 
750ng of E2 K111R, K111R/K112R, or K339R.  Luciferase 
activity was detected 24 hours post transfection.  Results are 
presented as a percentage of wild type E2 activation (not 
shown).  B Lysates from transfected cells were prepared for 
SDS-PAGE and immunoblot analysis was performed to confirm 
protein expression. 
  
Figure 2.10
K/R mutants.
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2.10).  An immunoblot demonstrating the increasing levels of E2 transfected in 
the dose response is presented in figure 2.10b.  To confirm that the K111R, 
K112R and K111R/K112R mutant proteins were being expressed, E2 transcript 
levels were determined by RT-PCR.  While all three transcripts were present at 
levels lower than wild type, they were detectable (Fig 2.9d). 
It is known that acetylation of proteins can affect their ability to interact with DNA 
(63).  To examine if E2 acetylation plays a role in its DNA interaction, we 
transfected C127 cells with the ∆Nco1 genome wild type E2 or one of the K/R 
mutants, and analyzed interaction by ChIP.  Wild type E2 interacted with the 
BPV-1 LCR strongly as expected (Fig 2.11).  E2 K70R interacted with DNA 
nearly as well as wild type.  Both K107R and K339R bound DNA about half as 
well as wild type as determined by visual inspection.  K391R actually appeared to 
bind the LCR better than wild type.  This mutation is in a non-conserved region of 
the C-terminus and is not near the DNA contact or dimerization sites (149).  
K112R was able to interact with DNA as well as wild type E2.  This would be 
expected given its transcriptional activity.  Finally, K111R and K111R/K112R 
were observed to interact with BPV-1 DNA in lower abundance than wild type E2 
(Fig 2.11).  These results are consistent with the reduced transcriptional activity 
and protein expression of these two mutants. 
Mutation of Lysines 111 and 112 Induces Cytosolic Mislocalization 
A sequence of basic amino acids in the N-terminus of BPV-1 E2 has been  
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Figure 2.11 Interaction of E2 mutants with DNA.  A C127 cells were 
transfected with ∆Nco1 genomes and either wild type E2 or the 
K/R mutant panel.  24 hours post transfection, cells were 
crosslinked and immunoprecipitated with E2 antibody.  Bound 
DNA was amplified using E2 primers.  Input (lower panel) 
represents 1% of the total lysate DNA used for precipitation. 
  
Figure 2.11 Interaction of E2 mutants with DNA.
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reported to function as a NLS in the absence of the highly conserved C-terminal 
NLS (172).  These two NLS sequences contain four of the six mutated lysines 
and prompted examination of their localization.  The subcellular distribution of 
four mutants, K70R, K107R, K339R, and K391R were nearly indistinguishable 
from that of wild type E2; nuclear localization was observed in nearly all cases 
(Fig 2.12a).  The three remaining mutant proteins K111R, K112R, and 
K111R/K112R deviate from wild type localization and exhibit a spectrum of 
subcellular distributions ranging from nuclear exclusion to exclusively nuclear 
(Fig 2.12a).  The severity of mislocalization, characterized here as the extent of 
observed nuclear exclusion, was different for each mutant protein.  K112R was 
observed to be more nuclear and the double mutant K111R/K112R was 
observed to be primarily excluded from the nucleus.  K111R displayed an 
intermediate phenotype although its localization pattern more closely resembled 
K111R/K112R than K112R (Fig 2.12a). 
Quantifying the extent of mislocalization was necessary to fully characterize 
these mutants due to the spectrum of localization patterns observed for K111R, 
K112R, and K111R/K112R.  The spectrum was divided into four discrete 
localization patterns and E2 mutant expressing cells were manually counted and 
assigned to each category by visual inspection and pre-determined selection 
criteria (Fig 2.12b).  Compared to wild type E2, all three mutant proteins 
displayed considerably more cytosolic accumulation (Fig 2.12c). K111R and 
K111R/K112R were consistently found to be evenly distributed throughout both  
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Figure 2.12 Several E2 lysine to arginine mutants are mislocalized to the 
cytosol.  A RPE-1 cells plated on coverslips were transfected 
with either wild type E2 or one of three lysine to arginine 
mutants.  24 hours post transfection, cells were fixed and stained 
using an antibody to E2 (Green) and DNA was visualized using 
DAPI (Blue).  B Mutant transfected RPE-1 cells representing the 
localization of categories 1 through 4 used for quantifying the 
severity of E2 mutant mislocalization.  1: excluded from the 
nucleus, 2: even distribution throughout the cytosol and nucleus 
(indicated by red arrow), 3: diffuse staining with greater intensity 
in the nucleus (indicated by red arrow), 4: exclusively nuclear 
staining.  C The degree of mislocalization was quantified for wild 
type E2, K111R, K112R, and K111R/K112R.  50 E2 positive 
cells were counted per coverslip and a minimum of 4 coverslips 
were counted for wild type E2 and each mutant, each coverslip 
represents an individual experiment.  The degree of 
mislocalization was scored into four categories as described 
above. Results are presented as a percentage of total cells 
counted. 
 A 
Figure 2.12 Several E2 lysine to arginine mutants 
are mislocalized to the cytosol.
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the nuclear and cytosolic compartments (Fig 2.12c). K111R/K112R was found to 
be excluded from the nucleus more often than either of the other mutants (Fig 
2.12c compare second and fourth panels).  While expression of the K112R 
mutant still resulted in significant cytosolic localization, E2 staining was more 
prevalent in the nuclear compartment (Fig 2.12c).  The increase in cytosolic 
localization for each mutant is not due to Crm-1 mediated nuclear export; 
treatment of mutant transfected cells with leptomycin B (LMB), which blocks this 
pathway, had no effect on the subcellular distribution of E2 mutant proteins (Fig 
2.13).  While manually counting cells allowed us to gauge the level of 
mislocalization of each mutant, the visual categorization is subjective.  In order to 
more specifically determine the mislocalization of the E2 mutants, quantification 
of cytosolic and nuclear fluorescence of randomly selected mutant transfected 
cells would be needed. 
HATs Affects E2 Localization 
Mutation of E2 at lysines 111 and 112 renders them unable to be efficiently 
retained in the nucleus. While there is a correlation between acetylation and 
nuclear retention, the specific role of p300 with respect to E2 localization is still 
unclear.  To address this, the localization of wild type E2 in p300 deficient RKO 
cells was examined.  Following transfection of BPV-1 E2 alone, some E2 was 
found to be localized to the cytosol (Fig 2.14 Top).  The distribution pattern was 
diffuse throughout both the nuclear and cytosolic compartments, although E2 
staining was more intense in the nucleus. Co-transfection of p300 into RKO cells  
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Figure 2.13 Localization of E2 K/R mutants is unaffected by Leptomycin B.  
A RPE-1 cells were transfected with wild type E2 or E2 mutants. 24 
hours post transfection cells were mock treated or treated with 
1ng/ml Leptomycin B for 2 hours.  The extent of mislocalization was 
visually scored and data in each category is presented as a 
percentage of the total number of cells counted.  1: excluded from 
the nucleus, 2: even distribution throughout the cytosol and 
nucleus, 3: diffuse staining with greater intensity in the nucleus, 4: 
exclusively nuclear staining.  B Representative images of untreated 
and cells treated with Leptomycin B.  Cyclin B is stained red and 
DNA is labeled blue in the overlayed image. 
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Figure 2.13 Localization of E2 K/R 
mutants is unaffected by Leptomycin 
B. 
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Figure 2.14 E2 is mislocalized to the cytosol in cells deficient in p300 and 
CBP.  RKO cells plated on coverslips were transfected with wild 
type E2 and either a p300 expression construct, empty vector or 
siRNA to CBP.  24 hours post transfection, cells were fixed and 
stained using an antibodies to E2 (Green) and p300 or CBP 
(Red), DNA was visualized using DAPI (Blue). 
  
Figure 2.14 E2 is mislocalized to the cytosol in cells deficient in p300 and 
CBP. 
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with BPV-1 E2 almost completely restored nuclear E2 localization (Fig 2.14 
middle).  The requirement of CBP to fully activate E2 dependent transcription 
coupled with the observation that CBP increases acetylation of E2 led us to ask if 
CBP could compensate for E2 with regard to affecting the localization of E2.  To 
address this we transfected siRNA directed toward CBP into RKO cells.  We 
observed that depletion of CBP resulted in a dispersed E2 localization pattern 
(Fig 2.14 bottom).  E2 staining was even throughout the nucleus and cytosol.  
This is similar to the patterns observed of E2 K111R and K112R. 
p300 is Not Limiting for E2 K/R Mutant Transcription and Localization 
It is possible that the transcriptional and localization phenotypes observed for E2 
K111R, K112R, and K111R/K112R were not due to the inability of p300 to 
interact with and acetylate E2.  To address this we attempted to restore 
transcriptional activity by over expression of p300.  Co-expression of p300 with 
wild type E2 enhances activation of E2 dependent transcription in RKO cells to 
an average of two fold higher than in the absence of p300 (Fig 2.15a).  E2 
K111R or K111R/K112R exhibited an 80% reduction in transcriptional activity as 
compared to wild type E2.  Furthermore, after introduction of p300 there was no 
significant increase in transcriptional activity of either K111R or K111R/K112R 
(Fig 2.15a).  The subcellular distribution of the E2 K111R, K112R, and 
K111R/K112R mutants was also examined in RKO cells.  Diffuse distribution 
patterns similar to wild type E2 were observed for all mutants and reintroduction 
of p300 into cells transfected with E2 mutants had no effect on E2 localization 
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Figure 2.15 Reintroduction of p300 is unable to rescue transcriptionally 
defective E2 mutants.  A RKO cells were transfected with an E2 
responsive luciferase reporter, either wild type or mutant E2, and 
either a p300 expression construct or empty vector.  Wild type E2 
sample was also co-transfected with control siRNA for 
comparison to siCBP transfected sample.  Luciferase activity was 
detected 24 hours post transfection.  Results are presented as a 
percentage of wild type E2 activation.  One way ANOVA was 
performed with Bonferonni post hoc analysis comparing all 
means *** p<0.001.  The differences between K111R plus and 
minus p300 and K111R/K112R plus and minus p300 are not 
statistically significant.  B RKO cells transfected with wild type E2 
or E2 mutants, in the presence or absence of p300 were 
prepared for immunofluorescence and stained for E2 (green).   
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Figure 2.15Reintroduction of p300 is 
unable to rescue transcriptionally 
defective E2 mutants. 
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(Fig 2.15b).  Interestingly, in comparison to mutant transfected RPE-1 cells, 
these cells appeared to be less severely mislocalized.  RPE-1 cells are 
immortalized by expression of hTERT, while RKO cells have defective p53 and 
p300.  There could also be additional genetic lesions in these cells that may 
contribute to the observed differences in localization. 
The ability of E2 to activate transcription in RKO cells which do not express p300 
is further evidence that there may be redundancy.  To investigate this we 
transfected RKO cells with siRNA to CBP.  Compared to control, transcriptional 
activation by wild type E2 was dramatically reduced upon CBP depletion (Fig 
2.15a).  This reduction was statistically significant (p<0.001) and was comparable 
to levels observed of E2 K111R and K111R/K112R (Fig 2.12a). 
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Discussion 
The cellular acetyltransferases p300, CBP, and pCAF, have been reported to 
interact with E2 proteins from several papillomavirus types.  While the 
significance of these interactions has not been fully characterized, it is known 
that these proteins are capable of enhancing transcription in an E2 dependent 
manner (113, 115, 145) and that the acetyltransferase activity of CBP and pCAF 
is required for transcriptional enhancement (113, 115).  We show that 
physiological levels of p300, CBP, and pCAF are necessary for E2 dependent 
transcriptional activation and that each protein appears to have independent 
functions in this process.  Several possibilities exist regarding the mechanism 
through which p300, CBP, and pCAF affect E2 dependent transcription.  First, E2 
may recruit one or more of these proteins to the viral promoter to acetylate 
chromatin.  This is likely to be true, as both p300 and CBP interact with the BPV-
1 LCR and CBP is enriched on the LCR in the presence of E2.  pCAF, however, 
was not found on the BPV-1 genome.  Second, acetyltransferases, especially 
p300 and CBP, may form and stabilize higher order transcriptional complexes.  
Specifically, p300, CBP, and pCAF have all been demonstrated to be necessary 
for activation of the interferon β enhancer where p300 and CBP form a scaffold 
for recruitment of ATF/JUN, NF-κB, and other factors (30).  Here, we 
demonstrate complex formation between the co-factor Gps2 and p300 and 
pCAF.  These complexes could have a variety of implications including dynamic 
regulation of acetylation.  Gps2 is also known to be in the N-CoR complex with 
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HDAC3 (213).  Dynamic switching between p300 and HDAC3 could be control 
the histone acetylation status at the BPV-1 promoter.  While all of these proteins 
are likely to form large complexes, the requirement for the acetyltransferase 
activity of CBP and pCAF for enhancement excludes the possibility that these 
proteins function as scaffolds exclusively.  Finally, E2 itself may be a substrate 
for acetylation which we demonstrate here. 
Acetylation of E2 by p300 presents a novel method of regulating papillomavirus 
transcription.  We report that 14 of 16 lysines in E2 are acetylated in vitro.  While 
this is suggestive that E2 is capable of being acetylated, it is unlikely that all of 
these lysines are acetylated under physiological conditions given that some of 
them are not on the surface of the protein.  We have screened several mutants 
with respect to biological significance of this potential modification.  Half of the 
mutants tested including K70R, K107R, and K391R were not significantly 
different from wild type E2 with respect to transcription or subcellular distribution.  
While transfection of the K339R had no effect on E2 localization, its 
transcriptional activity was reduced to approximately 50% of wild type activity and 
this defect was not entirely due to lower expression level or inability to interact 
with DNA; it has been demonstrated previously that this mutant is competent to 
interact with DNA containing E2 binding sites (172).  The remaining mutants 
including K111R, K112R, and K111R/K112R exhibited aberrant phenotypes in 
transcriptional activation and localization.  All three of these mutants were 
detectable by immunoblot; however, we were unable to detect increasing protein 
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levels following a dose response of E2 K111R/K112R.  This mutant may be 
shuttled to the cytosol and degraded.  K111R/K112R mutant protein levels are 
never high, and transcriptional dose response confirms this.  Further, it is also 
possible that higher levels of this mutant are toxic to cells.  This could result in 
preferential selection of lower expressing cells in a pooled lysate experiment 
such as immunoblot.  The reduced protein levels of K111R, K112R, and 
K111R/K112R are partially due to reduced expression from the CMV driven 
constructs.  This is consistent with previous reports for transcriptionally defective 
E2 mutants that are unable to enhance their own expression from plasmids (75).  
We have also found that mutation of lysine 111 alone and together with lysine 
112 resulted in significant decreases in transcriptional activation.  In contrast, 
mutation of lysine 112 alone resulted in an enhancement of transcription.  All of 
these mutations affected the localization of E2 to varying degrees.   
While it appears that acetylation of lysine 111 is necessary for transcription the 
result of acetylation at lysine 112 is not as straight forward.  It is possible that 
acetylation of lysine 112 may either promote an inhibitory conformational change 
or promote an interaction with a transcriptional repressor and mutation of this 
residue to arginine relieves this repression.  Conversely, acetylation of this 
residue may also inhibit interaction with a co-activator.  We speculate that E2 
acetylated at lysine 111 interacts with a co-factor, such as Brd4 through its 
bromodomain.  Acetylation at lysine 112 may inhibit this interaction resulting in 
reduced transcription.  Sequence preference of the HAT catalytic domain for 
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acetylation of lysine 111 over lysine 112 may explain the enhanced 
transcriptional activity of K112R.  The inability of p300 or CBP to acetylate E2 on 
lysine 112 may enhance acetylation at lysine 111 resulting in increased 
interaction with Brd4 and enhanced transcription.   
Interaction studies previously identifying the region on E2 to which Brd4 binds 
were carried out using a small peptide of Brd4 and were also done in vitro (1).  
Under these conditions E2 would not be acetylated and an interaction between 
Brd4 and acetylated lysine 111 would not be discovered.  It may be that Brd4 
interacts with E2 across all three alpha helices as previously described as well as 
lateral to alpha helix three where lysines 111 and 112 are exposed. Brd4 was 
shown to interact with E2 in a heterotetrameric complex (1).  The Brd4 peptide 
contacts two different regions on the alpha helices of the E2 N-terminal domain. 
Although the structures of several functional domains including both 
bromodomains and the C-terminal domain which interacts with E2 have been 
solved, the full length protein has not been crystallized and thus the exact folding 
of this molecule is unclear.  One Brd4 molecule may contact two regions of E2, 
or a second Brd4 molecule may contact E2 from a distinct E2-Brd4 heterodimer. 
Interaction of Brd4 and E2 through acetylated lysine 111 serves multiple 
functions.  First, Brd4 interaction with E2 is required for E2 dependent 
transcriptional activation (1, 166, 167).  Second, as a consequence of the 
interaction E2 is retained in the nucleus where it may enter another 
94 
 
transcriptional or replication complex.  Inability of Brd4 to interact with non-
acetylated E2 explains the transcriptional phenotypes.  We show that E2 is 
acetylated by p300 and likely by CBP as well.  Depletion of either of these two 
proteins would result in reduced interaction with Brd4, decreasing transcriptional 
activation.  There may be partial redundancy between p300 and CBP with regard 
to transcription which may, along with incomplete knockdown, explain why 
depletion of either of these proteins individually results in only 50% transcriptional 
reduction.  This hypothesis is supported by 80% reduction in E2 dependent 
transcriptional activation following depletion of CBP in RKO cells where p300 is 
not expressed.  The residual transcription here may be attributable to inefficient 
depletion of CBP, shown in figure 1 to be approximately 50%.  We did not 
perform double or triple knockdowns in this study; these experiments would be 
useful in determining the contributions of each of p300 and CBP.  Transcription in 
the absence of p300 and CBP in RKO cells is comparable to the activity of E2 
K111R or the double mutant K111R/K112, further suggesting that acetylation of 
these residues is necessary for E2 dependent transcriptional activation.   
Interaction with other factors including Brd4 may tether E2 into transcriptional 
and replication complexes.  Loss of this interaction as with E2 K111R, K112R, or 
K111R/K112R, would disrupt this tether allowing E2 to be lost to the cytosol.  The 
subcellular distribution of K111R, K112R, and K111R/K112R was nearly identical 
to that observed of wild type E2 when it was transfected into cells deficient for 
p300.  This correlation indicates that acetylation of lysine 111 and possibly lysine 
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112 by p300 may be necessary to efficiently retain E2 in the nucleus.  These 
results are consistent with localization E2 N-terminal deletions which lack lysines 
111 and 112 (172).  Localization of E2 may be regulated in part through 
acetylation of these residues; however, the lack of complete inclusion or 
exclusion of the mutants and that leptomycin B had no effect on localization 
indicates that the defects observed are likely not due to nuclear export, and that 
reduction in NLS strength through the lysine to arginine mutation, or passive 
diffusion of E2 through the nuclear pore complex may be responsible.  This 
suggests that instead of these modifications directly controlling the localization of 
E2, its mislocalization may result from the inability of E2 to be retained in the 
nucleus when it is not in an active complex.  One may speculate that this is a 
method of regulating E2 protein levels within the nucleus and the cell. 
The lack of complete exclusion from the nucleus observed upon transfection of 
the E2 K111R/K112R mutant and the residual transcriptional activity suggests 
that acetylated lysine 111 alone does not mediate interaction with Brd4 
bromodomain.  Another factor or perhaps an additional modification may be 
necessary to control E2 dependent transcription.  A possible target on BPV-1 E2, 
aside from the previously described Brd4 interaction region (1), is lysine 107.  
The E2 mutant K107R, while observed to be primarily nuclear also accumulated 
in the cytosol at a low frequency (data not shown), consistent with localization of 
an E2 deletion mutant lacking amino acids 101 to 110 (172).  Additionally, this 
mutant exhibited a small deficiency in transcriptional activity.  While 
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bromodomains have high affinity for most acetylated lysines, they do exhibit 
context sequence preference (121, 136).  The interaction of a bromodomain with 
acetylated lysine prefers a pair of acetylated lysines with several spacer residues 
between them (42, 134).  This would indicated that acetylation of both lysine 107 
and 111 would result in a higher affinity interaction.  Further characterization of 
K107R was not pursued because the phenotype was not dramatically different 
from wild type.  While acetylation at lysine 107 does not appear to have a 
dramatic effect on E2 transcription by itself, perhaps interaction with Brd4 would 
be stronger in combination with acetylation of lysines 111. 
We have outlined here a potential role for the cellular acetyltransferase p300 and 
potentially CBP in E2 dependent transcription.  A specific role for pCAF in E2 
dependent transcriptional control was not identified in this study.  This HAT was 
not found to interact with BPV-1 DNA.  This does not rule out its interaction 
altogether due to its tendency to form higher molecular weight complexes with 
p300 and CBP.  It is possible that the sensitivity of the ChIP assay was not high 
enough to detect pCAF in this manner.  While data indicates that p300, CBP, and 
pCAF may function independently, there does appear to be some redundancy.  
CBP may also be capable of acetylating E2 given the functional overlap between 
this protein and p300.  Additionally, the reduction in transcriptional activation in 
RKO cells following CBP depletion suggests that CBP may be compensating for 
p300 in these cells.  Acetylation of E2 by pCAF or Gcn5 may require a second 
factor to facilitate complex formation or may only occur on a small subset of 
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available lysines.  A more sensitive assay may be required to definitively 
eliminate pCAF in this capacity. 
p300, CBP, and pCAF may each play multiple roles during E2 dependent 
transcriptional activation and a sequence of events including acetylation of E2 by 
p300 and E2 dependent chromatin modification by several of these proteins may 
be necessary to fully activate viral transcription.  Additionally, acetylation of two 
lysines within the N-terminus of E2 control transcriptional activation likely through 
regulation of co-factor entry into complexes.  This study presents a novel method 
of regulating E2.  
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CHAPTER III 
Characterization of a Novel Interaction Between BPV-1 E2 and RINT1 
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Introduction 
Many cellular proteins have been identified as E2 interacting proteins.  These 
cellular interaction partners have provided a wealth of information about E2 
activity.  Several E2 interacting proteins and the significance of their interactions 
have already been discussed.  Here the E2 interacting protein RINT1 and the 
biological complexes in which it exists will be further described.   
RINT1-Rad50 Complex 
Rad50 interacting protein 1 (RINT1) was identified in a screen for interacting 
proteins of the human structural maintenance of chromosomes (SMC) family 
member Rad50 (206).  RINT1 is encoded by 792 amino acids and has a 
molecular weight of 87 kDa.  There is a series of leucine heptad repeats at the N-
terminus of RINT1, but no other functional domains have been identified.  
Homozygous deletion of RINT1 results in mice that die early in development; 
embryos fail to develop past day E5.5 (122).  Blastocysts taken from RINT1 
knockout embryos failed to expand after four days of culture indicating that 
RINT1 is essential for proliferation early in embryogenesis.  Further, 81 % of 
RINT1 heterozygous mice were observed to develop multiple tumors over an 
average lifespan of two years.  Taken together these data indicate that RINT1 
may be a tumor suppressor gene.  
RINT1 was found to be expressed in a variety of cell types and throughout the 
cell cycle; however, its interaction with Rad50 appears to be limited to the G2/M 
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phases (206).   Rad50 is a highly conserved protein that has been demonstrated 
to be critical for cellular proliferation.  Its presence in complex with hMre11 and 
NBS1, indicates a role in DNA damage repair, specifically double strand breaks.  
The interaction between RINT1 and Rad50 and more specifically the temporal 
nature of this interaction suggests that RINT1 may also play a role in the DNA 
damage response.  Cell lines were developed that stably express a truncation 
mutant of RINT1 which lacks the N-terminal 256 amino acids.  This protein is still 
able to interact with Rad50 and therefore acts as a dominant negative.  Following 
exposure of these cells to ionizing radiation, there is a marked decrease in 
bromodeoxyuridine (BrdU) incorporation indicating that the Rad50-RINT1 
complex was not affecting the G1/S cell cycle checkpoint (206).  To examine a 
possible role for this complex in the G2/M checkpoint cells were again exposed 
to ionizing radiation and a mitotic index was calculated.  As compared to cells 
expressing a vector alone, those expressing the truncated RINT1 had a 
significantly higher mitotic index indicating that this protein in complex with 
Rad50 may be important for G2/M cell cycle control (206).  In addition to its role 
in DNA damage repair, Rad50 has been implicated in cell cycle control 
specifically in complex with the tumor suppressor Brca1.  RINT1 may be present 
in this complex or function independently in cell cycle control. 
RINT1-p130 Complex 
RINT1 has subsequently been found in several other protein complexes in 
diverse cellular processes.  The pocket protein p130, which is related to the 
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tumor suppressor pRB, has been implicated in the suppression of telomere 
lengthening in the absence of telomerase (57).  In order to further investigate its 
role in this process, a screen was performed to identify p130 interacting proteins, 
one of which was determined to be RINT1 (102).  Subsequently, RINT1 was 
determined to interact with p130 in vitro and in vivo and preferentially with the 
hypophosphorylated form of p130, which is the active form that binds to E2F 
family transcription factors and inhibits cellular proliferation (102).  RINT1 
interacts very weakly with other pocket protein family members pRB and p107 
(102).  p130 was also found to complex with Rad50 and this interaction appears 
to be RINT1 dependent (102).  Finally, depletion of RINT1 results in lengthened 
telomeres without increasing telomerase activity.  This phenotype was dependent 
on the interaction of RINT1 with p130 (102).  The inability of a single point mutant 
of RINT1 that is incapable of interaction with p130 to prevent telomere 
lengthening strengthens the argument that RINT1 is a tumor suppressor. 
It is not known currently what role the RINT1-p130 complex may play in 
papillomavirus biology; however, p130 like its pocket protein family member pRB, 
interacts with the papillomavirus oncoprotein E7 (156).  E7 was found to 
preferentially bind to p130 over pRB and p107 in co-immunoprecipitation 
experiments (174).  While pRB is expressed throughout the cell cycle, p130 
expression is limited to quiescent and differentiating cells where high and low risk 
E7 proteins promote S-phase reentry by targeting p130 for degradation (59, 156, 
212).    
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RINT1-Syntaxin-18 Complex 
RINT1 was also identified in a screen for proteins that interact with human 
syntaxin-18 (79).  Syntaxin-18 is an endoplasmic reticulum (ER) localized target 
membrane associated soluble N-ethylmaleimide-sensitive attachment protein 
receptor (t-SNARE) that is involved in membrane trafficking between the Golgi 
and ER.  t-SNAREs specifically interact with vesicle associated v-SNAREs 
directly leading to membrane fusion between these two membrane 
compartments.  Zw10 and p31, a kinetochore associated protein and another 
SNARE protein respectively, were also identified in this screen as syntaxin-18 
interacting proteins (79).  RINT1, Zw10, and p31 were found to form a sub-
complex that remained together following dissociation from syntaxin-18.  Over-
expression of Zw10 or disruption of the interaction between Zw10 and RINT1 
results in the disruption of vesicular trafficking between the ER and the Golgi 
(79).  
The syntaxin-18 complex was further characterized in a series studies identifying 
several other proteins that are present and appear to be critical for the stability of 
the ER, Golgi and membrane dynamics.  First, the BH3 only protein BNIP1 was 
determined to link the p31, Zw10, RINT1 sub-complex to syntaxin-18 (138).  
RINT1, which interacts directly with Zw10, was also shown to be critical for 
recruiting Zw10 into this sub-complex (8, 138).  Transfection of a dominant 
negative truncation of RINT1 consisting of the N terminal 219 amino acids  or 
siRNA mediated depletion of RINT1 result in defects in vesicular transport 
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between the ER and Golgi concomitant with a redistribution of Zw10 from the 
ER(8).  Immunoprecipitations using antibodies to syntaxin-18, p31 or BNIP1 were 
unable to efficiently co-precipitate Zw10 in RINT1 depleted cells (8).  Conversely, 
the same antibodies were able to co-precipitate RINT1 in Zw10 depleted cells 
(8).  siRNA mediated knockdown of RINT1 or over-expression of an N-terminal 
fragment of RINT1, which was shown to interact with Zw10, resulted in the 
redistribution of Zw10 from the ER and disruption of vesicle transport(8). 
While the nature of the syntaxin-18 complex was becoming clearer, at least one 
key question remained.  It is known that there are sub-complexes (8, 138) and 
that RINT1 and Zw10 interact directly (79), but how these two proteins are 
recruited into the complex was unknown.  Neither interacts directly with p31, 
syntaxin-18, or BNIP1 (79, 138).  Neuroblastoma-amplified gene (NAG) was 
identified as a link between the SNARES (p31, syntaxin-18) and the peripheral 
proteins (RINT1, Zw10) (6).  NAG was found to interact with both p31 and 
RINT1/Zw10 through its N and C termini respectively (6).  Further, p31 was 
unable to immunoprecipitate RINT1 or Zw10 in cells depleted of NAG (6).  
Finally, depletion of NAG caused both RINT1 and Zw10 to dissociate from the 
ER (6).  This phenotype is similar to that observed of Zw10 upon depletion of 
RINT1 (8).  Taken together these data indicate that NAG links the peripheral 
RINT1 and Zw10 sub-complex to the core SNARE complex including syntaxin-18 
and p31.   
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While initial finding indicated the importance of the syntaxin-18 complex in 
anterograde transport, subsequent work has since proven their requirement for 
retrograde transport and that the initial reported defects in anterograde transport 
were indirectly caused by an inhibition of retrograde trafficking from the Golgi to 
the ER (182).  Zw10 and RINT1 were shown to be downstream effectors of a 
small GTPase, Rab6.  It was found that depletion of Rab6, which is a Golgi 
associated regulator of retrograde trafficking, suppressed the effects of 
Zw10/RINT1 depletion mediated Golgi dispersal (182).  The authors suggest a 
model by which Rab6 initiates the recycling of Golgi proteins to the ER where the 
syntaxin-18 complex including Zw10/RINT1 receive the cargo and tether it to the 
ER membrane for fusion (182).   
In addition to this role in the recycling of Golgi proteins, RINT1 appears to have 
an important role in the maintenance of Golgi and centrosomal integrity through 
the cell cycle.  RINT1 is found to co-localize to the centrosome throughout the 
cell cycle (122).  It is known that depletion of RINT1 induces a disruption of the 
Golgi though the defective vesicular recycling pathway (122).  However, 
depletion of RINT1 also results in severe defects in Golgi and centrosomal 
dynamics throughout mitosis.  Loss of RINT1 results in prolonged mitosis, and 
eventual cell death (122).  Additionally, there is an increase in the number of 
observable centrosomes in RINT1 depleted cells suggesting a role for RINT1 in 
faithful centrosomal duplication (122).  This aberrant centrosomal duplication 
directly led to an increase in the number of spindle poles in mitosis and 
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subsequent chromosomal instability (122).  Pericentriolar localization is thought 
to be critical for proper Golgi disassembly in mitosis and subsequent reassembly 
(29, 74, 89).  Depletion of RINT1 also results in a disconnection of the Golgi from 
the centrosome (122).  It is thought that RINT1 may coordinate faithful 
segregation of  the Golgi and the centrosome during mitosis.  The presence of 
syntaxin-18 and Zw10 in this RINT1 complex in this process is unclear.   
Syntaxin-18 has also been found in complex with the BPV-1 minor capsid protein 
L2 (22, 109).  Both syntaxin-18 and L2 were both found to co-localize to the ER 
(22).  This was a surprising result because L2 contains two nuclear localization 
signals.  The interaction domain between these two proteins was determined to 
involve a highly conserved region from amino acids 40 to 44 (22).  Mutation of 
this domain results in generation of non-infectious pseudovirions (22).  These 
pseudovirions are able to attach and enter the cell; however, they are unable to 
subsequently interact with syntaxin-18 (22).  Further, microinjection of a peptide 
antibody raised against this interaction domain is capable of neutralizing viral 
infection as a direct result of interference with the L2 syntaxin-18 interaction 
(109).  The authors suggest that syntaxin-18 and its interaction with L2 is 
necessary for infection.  This interaction takes place after vesicular escape and 
that syntaxin-18 facilitates trafficking of the L2-genome complex or partially 
disassembled virions to the nucleus for import (109). 
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RINT1-E2 Complex 
The nature of the interaction between BPV-1 E2 and RINT1 remains unclear.  
RINT1 was initially identified in this lab not as an E2 interacting protein, but in a 
screen for proteins that interact with hChlr1 (shortly after its identification in 
Rad50 and Syntaxin-18 complexes).  hCHLr1 has been shown in our lab to 
tether the viral genome to the host chromatin during mitosis.  Our lab and others 
have also shown that this protein as a key factor in establishing sister chromatid 
cohesion early in mitosis.  In order to further characterize hCHLr1 and its role in 
cohesion and BPV-1 episomal maintenance, a screen was performed to identify 
other proteins that interact with hCHLr1.  One positive interacting protein was 
RINT1.  RINT1 had already been established to play a role in vesicular transport 
with binding partners Syntaxin-18 and Zw10.  Its interaction with the latter 
protein, which is also a critical factor for signaling spindle attachment to the 
kinetochore to the spindle checkpoint proteins, prompted investigation into the 
possibility that RINT1 interacted with E2.  It was thought at the time that RINT1 
may form a complex with hCHLr1 and Zw10 to facilitate viral genome 
maintenance and coordinate tethering with the spindle assembly checkpoint. We 
were subsequently able to confirm that a 185 amino acid fragment of RINT1 
interacted with BPV-1 E2.        
Preliminary results from our lab show that RINT1 forms complexes with hCHLr1 
and with BPV-1 E2.  Here, we characterize the binding domains on E2 to which 
RINT1 interacts.  A panel of transcriptionally active and defective point mutants 
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was screened to gain insight into the nature of this interaction.  Finally we 
addressed the possibility that RINT1 may be post-translationally modified in 
complex with E2.  We identify that several N-terminal mutants of E2 do not 
interact with RINT1 or interact very weakly.  While we were unable to identify the 
biological significance of this interaction, we present a foundation for future work 
in this area.  The interaction between RINT1 and E2 may present a link between 
the viral regulatory protein and the vesicular transport pathway.  
  
108 
 
Materials and Methods 
Cell Culture and Antibodies C33a cells were used in all immunoblot and 
immunoprecipitation experiments, the cells are from spontaneously immortalized 
(HPV negative) cervical carcinoma biopsies.  They were cultured in Dulbecco’s 
Modified Eagle Medium (Invitrogen) supplemented with 10% Fetal Bovine Serum 
(Atlas Biologicals) and penicillin/streptomycin solution (Invitrogen).  DNA for 
transfections was diluted in Optimem Serum Free Media (Invitrogen) and 
transfections were performed using Lipofectamine 2000 transfection reagent 
(Invitrogen). 
Primary antibodies used include BPV-1 E2 B201 from lab prepared stock, RINT1 
was detected using 12CA5 anti-HA, 9E10 anti-myc, 2074 anti-RINT1 peptide 
antibody (raised against peptide CKRPENYFKHIKEA starting at amino acid 720 
in the C-terminus of RINT1) or anti-RINT1 as published (79) prepared from 
hybridoma cell line.  Secondary antibody used was horseradish peroxidase 
conjugated goat anti-mouse IgG (The Jackson Laboratory). 
Immunoprecipitation and Immunoblot Analysis C33a cells were plated on 10 
cm tissue culture dishes.  The following day cells were transfected with a 
combination of pCG vector, pCDNA3-HARINT1, and E2 or E2 mutants.  24 hours 
post transfection, cells were harvested by rinsing with phosphate buffered saline 
(PBS), scraping into a small volume of PBS for transfer to an Eppendorf tube.  
Cells were lysed using IPLB (50mM Tris-HCl pH 8.0, 0.1mM NaCl, 20mM NaF, 
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10mM KH2PO4, 1% Triton X-100, 10% Glycerol, 0.1mM DTT, 2mM PMSF, and 
Complete protease inhibitor cocktail Roche).  Lysates were clarified by 
centrifugation at 15,000 x g for ten minutes. Lysates were then diluted 1:1 with 
IPBB (50mM Tris-HCl pH 8.0, 0.1mM KCl, 0.1mM EDTA, 0.2% NP-40, 0.5 µg 
BSA, 2.5% Glycerol, 0.1mM DTT, 2mM PMSF), specific antibodies were added 
and complexes were formed with gentle agitation overnight at 4oC.  Protein A or 
Protein G sepharose beads (Invitrogen) were added the following day and 
complexes were collected for 1 hour.  After extensive washing with IPWB (0.1mM 
Tris-HCl pH 8.0, 0.1mM NaCl, 0.2% NP-40, 0.1mM DTT, 2mM PMSF) 
complexes were separated by SDS-PAGE and membranes were probed for 
target proteins.  For each individual lysate, 5% of the total volume used for each 
immunoprecipitation used was reserved for use as input protein.  This sample 
was separated by SDS-PAGE with the immunoprecipitated complexes for 
reference of protein expression. 
Immunoprecipitated complexes for phosphatase treatment were prepared in the 
same manner as above.  In the place of sepharose beads for collection, protein A 
or protein B magnetic Dynabeads (Invitrogen) were used to clear the entire 
volume of buffer from the complexes.  Following the final wash the complexes 
were split to two tubes. NEB buffer 3 was added with 20 units of calf intestinal 
phosphatase (New England BioLabs) in a total reaction volume of 50 µL.  2 µL of 
water was added to one reaction of every pair in place of phosphatase. The 
reactions were incubated at 37oC for 60 minutes and then separated by SDS-
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PAGE. The effect of phosphatase treatment was detected by immunoblot using 
an anti-HA antibody. 
In Vitro GST-Pull Down Glutathione S-transferase (GST) fused fragments of E2 
were synthesized essentially as described previously (26). E. coli strain BL21 
(DE3) containing pLysS and pGEX2T-TAD or pGEX2T-DBD were grown up to an 
optical density at 600nm equaling approximately 0.6.  Protein expression was 
induced overnight at 30oC using 1mM IPTG.  Cells were collected, lysed in NETN 
(100mM NaCl, 0.1mM EDTA, 20mM Tris-HCl pH 8.0, 0.1% NP-40), sonicated in 
the presence of lysozyme, and lysates were clarified by centrifugation.  E2 DBD 
was purified by incubating with glutathione beads at 4oC overnight.  E2 TAD, was 
purified as above except after clarifying lysate, the supernatant was decanted 
and the pellet was solubilized with 8M urea.  E2 TAD was purified from this lysate 
by incubating with glutathione beads at 4oC overnight. After extensive washing 
protein concentration was estimated using Bio-Rad protein assay. A sample of 
each purified protein was then separated by SDS-PAGE and visualized by 
Coomassie Brilliant Blue R-250 total protein stain (Fischer Scientific). 
In vitro transcription and translation of RINT1 and luciferase were performed 
using 35S-labeled methionine and TnT Coupled Reticulocyte Lysate system 
(Promega) as described in the manufacturer’s protocol. Templates included 
pSP65-RINT1 containing a Sp6 promoter and pTNT-Luciferase containing a T7 
promoter. 5 µL of each reaction was then incubated with GST-E2 proteins or 
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GST alone at 4oC overnight.  Complex bound beads were then thoroughly 
washed with NETN with 300mM NaCl.  Complexes were then separated by SDS-
PAGE, the gel dried, and exposed to a phosphor screen (Fuji).  Signal on the 
phosphor screen was then detected using a Fuji Phosphorimager. 
Luciferase Reporter Assay C33a cells were plated in triplicate on 6-well tissue 
culture plates. The following day, cells were transfected with 150ng pGL2-4BS 
E2 responsive luciferase reporter, 75ng pCG-E2b wild type E2 expression 
construct, pcDNA3-HARINT1, or pcDNA-TFIIB.  24 hours post transfection, cells 
were harvested with Reporter Lysis Buffer (Promega) and subjected to one 
freeze thaw cycle.  30 µL of each lysate was then added to one well of a 
CulturPlate-96 (Perkin Elmer).  Just prior to detection, 100 µL of Luciferase 
Assay Reagent (Promega) was added to wells and then reporter expression was 
detected on an EnVision Multilabel Plate Reader (Perkin Elmer).  Means were 
calculated from each triplicate and error bars represent standard deviation from 
the mean.  Data is presented as a percentage of reporter expression in the 
presence of wild type E2 alone. 
Yeast Two-Hybrid S.cerevisiae strain DBY1, which was constructed by 
inactivation of the TRP1 gene of BGW17a (MATa, leu2, 2-leu2, -11; his4–his519, 
ade1–-ade100,ura3–ura52) (25), was transformed with pBSY72 which is a β-Gal 
reporter containing E2 specific binding sites.  Transformants were selected using 
yeast minimal media in the absence of uracil, and the process was repeated for 
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transformation of wild type E2, E2 F87S, E2 55, E2 113, and E2 162 in the 
YEplac112G vector all containing a tryptophan selection marker.  After 
transformation of RINT1, in the plasmid pACT-RINT1, where it is fused to the Gal 
activation domain, transformants were selected on appropriate dropout medium 
and ten colonies were streaked onto selective media containing X-Gal (5-bromo-
4-chloro-3-indolyl-b-D-galactopyranoside).  After development of blue color, the 
darkness of the hue was visually inspected and scored into three categories 
based on the strength of interaction.  Controls for this assay include, lamin 
interaction with E2 and RINT1, Gps2 interaction with E2, hCHLr1 interaction with 
RINT1 and transformation of empty pGBKT7 and pGADT7 vectors. 
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Results 
RINT1 Interacts with the Transactivation Domain of E2 
While initial yeast two-hybrid experiments show that E2 interacts with a region 
within the N-terminal half of RINT1 (amino acids 194-379), the interaction surface 
on E2 has not been characterized.  Proteins have been reported to interact with 
either the N-terminal transactivation (TAD) domain or the C-terminal DNA binding 
and dimerization domain (DBD).  Identifying the domain with which RINT1 
interacts with will provide insight to the biological significance of this interaction.  
The domain on E2 that interacts with RINT1 was probed in vitro.  Glutathione S-
transferase (GST) tagged E2 TAD and DBD fragments were purified from E. coli 
and allowed to interact with isotopically labeled RINT1 or Luciferase control.  
GST alone was unable to interact detectably with either luciferase or RINT1.  
Further, labeled luciferase was undetectable or very inefficiently precipitated with 
GST-TAD or GST-DBD (Fig 3.1) indicating that there is insignificant background 
in this assay.  RINT1 was precipitated following incubation with GST-TAD but not 
GST-DBD (Fig 3.1).  
The domain with which RINT1 interacts on E2 was further characterized using a 
yeast two-hybrid interaction assay.  Several truncation mutants consisting of 
increasing deletion of the TAD were transformed with an N-terminal truncation of 
RINT1 which was the original yeast two-hybrid hit.  Lamin A/C was used as a 
negative control and did not interact with RINT1 or E2 (Data not shown).  hCHLr1  
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 Figure 3.1 RINT1 interacts with E2 in vitro.  Purified GST tagged E2 TAD 
(1-216), E2 DBD (286-410), or GST alone was incubated with 35S 
labeled RINT1 or Luciferase.  E2 was precipitated with glutathione 
resin and the interaction detected by phosphorimaging.  Input 
represents 20% of in vitro translated 35S  RINT1 or Luciferase used 
in reactions. 
  
Figure 3.1RINT1 interacts with E2 in vitro.
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was used as a positive control for interaction with RINT1 and was found to 
strongly interact (Data not shown).  Similarly Gps2, which was used as a positive 
control for E2 interaction, was found to interact strongly with E2, validating this 
assay (Data not shown).  In addition to wild type E2, the transactivation defective 
mutant F87S was also used.  E2 is able to activate the lactose operon in the 
absence of an activation domain fused “prey” protein.  Wild type E2 and F87S 
both interacted strongly with RINT1 as expected (Fig 3.2).  Deletion of the 54 or 
112 amino acids from the N-terminal TAD, resulted in a decrease in interaction 
with RINT1.  This decrease was approximately 50% as determined by visual 
inspection (Fig 3.2).  Further deletion of the N-terminal 161 amino acids disrupted 
the interaction (Fig 3.2).  A summary of the yeast two hybrid results is presented 
in table 3.1.  
RINT1 and E2 Form a Complex In Vivo 
The interaction between RINT1 and E2 has been confirmed in vitro and in yeast.  
While this strongly suggests the interaction will exist in vivo the nature of such a 
complex and its biological relevance is still unclear.  Complex formation between 
E2 and RINT1 was investigated in vivo using mammalian cell co-
immunoprecipitation.  RINT1 and E2 were efficiently co-precipitated using E2 
antibodies in C33a cell lysates where both proteins were transfected (FIG 3.3a).  
RINT1 was not co-precipitated with E2 antibodies in negative control IPs which 
included mock transfected lysates and lysates transfected with E2 or RINT1 
alone.  Cells were also co-transfected with RINT1 and three E2 point mutants. 
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Figure 3.2 RINT1 interacts with E2 in yeast.  S.cerevisiae yeast strain DBY1 
was transformed with an E2 responsive β-galactosidase reporter, E2, 
E2 F87L, or E2 truncations, as well as RINT1 fused to the Gal4 
activation domain and selected on SD agar plates in the absence of 
tryptophan, histidine, or leucine.  10 transformants were then streaked 
onto selective plates containing X-Gal. 
  
Figure 3.
 
2 RINT1 interacts with E2 in yeast. 
118 
119 
 
Table 3.1 Summary of Yeast Two-hybrid Binding Assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Construct Score 
WT +++ 
F87L +++ 
55-410 + 
113-410 + 
162-410 - 
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Figure 3.3 RINT1 interacts with E2 in mammalian cells.  A C33a cells were 
transfected with empty vector or a combination of HA-RINT1, wild type 
E2, or several E2 point mutants.  24 hours post transfection cells were 
immunoprecipitated with an E2 antibody (B201).  Interaction was 
detected by probing precipitated complexes with an anti-HA antibody to 
detect RINT1.  Lower two panels are 10% input probed for E2 and HA-
RINT1.  B C33a cells were transfected as previously.  Protein content 
of each lysate was estimated prior to immunoprecipitation.  The amount 
of lysate added to each reaction was then normalized to total protein.  
Complexes were precipitated with an E2 antibody (B201) and probed 
for RINT1with an anti-HA antibody.  The top panel represents input 
from each lysate. 
  
B 
A 
Figure 3.3 RINT1 interacts with E2 in mammalian cells.
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E39G is defective for transcription, but competent for transient replication.  This 
mutant was also used as bait for detection of RINT1by yeast two-hybrid screen.  
W99C is unable to interact with the general transcription factor TFIIB and is 
defective for both transcription and replication activity (209).  W130R is unable to 
interact with hCHLr1 and is competent for transcription and transient replication; 
however, mutant genomes containing this lesion are unable to be maintained 
episomally (143).  Transcriptionally defective mutants E39G and W99C were 
expressed at lower levels than wild type E2 which is consistent with other 
transcriptionally defective E2 mutants (25, 70).  Additionally, co-expression of 
these mutants resulted in reduced expression from the CMV promoter driven 
RINT1 expression construct used in this experiment (Fig 3.3a).  This 
phenomenon is also consistent for co-expression of other transcriptionally 
defective E2 point mutants.  W130R was expressed to levels comparable to wild 
type E2 and was also able to enhance RINT1 expression.  Immunoprecipitation 
using an E2 antibody efficiently co-precipitated RINT1 in E2 W130R co-
transfected cells; however, in cells co-transfected with either of the two 
transcriptionally defective mutants, E39G or W99C, E2 antibodies were either 
unable to co-precipitate RINT1 or unable to efficiently co-precipitate RINT1 in 
quantities detectable over background (Fig 3.3a).  Given that transcriptionally 
defective mutants resulted in dramatically reduced protein levels of E2 and 
RINT1, we next asked if normalizing the input lysate of the immunoprecipitation 
for total protein content would allow detection of RINT1 interaction with these two 
123 
 
mutants.  The experiment was repeated under the same conditions; however, 
prior to immunoprecipitation, equal amounts of total protein were separated on a 
gel and the relative RINT1 protein levels in each lysate were estimated by 
measuring the intensity of each band on the chemiluminescent image.  The 
volume of each sample lysate used for immunoprecipitation was then calculated 
based on the ratio of RINT1 protein present in that sample compared to wild type 
E2 transfected lysates.  Following precipitation with E2 antibodies samples 
transfected with both wild type E2 and E2 W130R were able to efficiently co-
precipitate RINT1 (Fig 3.3b).  With increase input lysate, RINT1 was also 
detectably co-precipitated in samples transfected with E39G and W99C.  These 
proteins still appear to only co-precipitate very small amounts of RINT1 as 
evidenced by the need of a long exposure to visualize RINT1 co-precipitated with 
E2 E39G (Fig 3.3b). 
RINT1 Interacts Preferentially with Transcriptionally Active E2 Mutants 
The differential interaction of RINT1 to E2 W130R versus E39G and W99C 
introduced the possibility that RINT1 may only interact with E2 in transcriptionally 
active complexes.  This phenomenon has also been demonstrated with Brd4 
where its interaction with E2 correlates with E2 transcriptional activity (167).  We 
sought to investigate if this was the case with RINT1 by screening a panel of both 
transcriptionally competent and transcriptionally defective E2 N-terminal point 
mutants.  In accordance with the previous experiment, mutants E39G and W99C 
were both found to interact with RINT1 (Fig 3.4a lanes 1 and 7).  Point mutants  
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Figure 3.4 Interaction of RINT1 with E2 mutant panel.  C33a cells were 
transfected with RINT1, several A transactivation defective point 
mutants, several B transactivation competent point mutants, or 
wild type E2. 24 hours post transfection cells were 
immunoprecipitated with an E2 antibody (B201).  Interaction was 
detected by probing precipitated complexes with RINT1 antibody.  
Immunoprecipitation is the top panel in A and B.  The remaining 
panels represent 10% input probed for E2 and RINT1.  
  
A 
B 
Figure 3.4 Interaction of RINT1 with E2 muta
 
nt panel. 
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Q66R, S93P, and W145R were found to interact with RINT1 with similar 
efficiency to W99C.  All of these mutants had similar expression of E2 and 
RINT1, except for co-transfection of W145R which had noticeably lower protein 
levels of each protein.  Mutants L97A and P106S co-precipitated RINT1 to similar 
levels as E39G which interacted with RINT1 less efficiently than W99C.  
Expression of L97A was similar to that of P106S co-expressed RINT1 in these 
samples was also present at similar levels.  Interestingly, E2 mutants F87S and 
W92R were either unable to precipitate RINT1 or interacted very weakly.  F87S 
was unable to interact with RINT1 despite higher levels of both proteins (Fig 
3.4a).  The level of co-precipitation despite low levels of RINT1 might suggest 
that E2 recruits a majority of available RINT1 into complexes.  In order to further 
characterize the interaction between E2 and RINT1 and to possibly identify more 
residues that are important for this interaction we screened a panel of 
transcriptionally competent E2 mutants.  These mutants are expressed at much 
higher levels than transcriptionally defective mutants for reasons outlined earlier.  
Additionally, co-expression of these mutants does not have a deleterious effect 
on transcription of the RINT1 expression construct.  E2 transcriptionally 
competent point mutants are expressed at similar levels and result in RINT1 
levels that are generally equal as well.  While transcriptionally negative mutants 
interacted with RINT1 to nearly equal levels throughout the panel with few 
exceptions, the transcriptionally competent mutants appear to be clustered into 
groups that interact with RINT1 at levels higher than wild type: D24A, A46E, and 
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N127Y, and levels about half wild type levels: W130R, Y131H, and E176G (Fig 
3.4b).  One mutant, R179G, appears to interaction with RINT1 very inefficiently if 
at all indicating its importance for interaction with RINT1.  A summary of the 
relative transcriptional activities of each BPV-1 E2 point mutant is presented in 
Table 3.3.   
Post-Translational Modification of RINT1 in E2 Complexes 
During investigation into the nature of the interaction between RINT1 and E2, a 
higher molecular weight banding pattern was consistently observed.  RINT1 was 
initially described to migrate as a doublet the slower migrating band resulting 
from upstream non-canonical initiation codon (206).  Incremental banding is most 
apparent in samples transfected with wild type E2 (Fig 3.4b), it is also visible in 
mutant transfected samples as well.  This pattern seems to be limited to 
transcriptionally active mutants and those that are expressed at higher levels (Fig 
3.4b).  This may suggest that if a post-translational modification is present it may 
be E2 dependent.  A previous report had attempted to detect phosphorylation of 
RINT1 by treating lysates with calf intestinal phosphatase (CIP).  This study was 
unable to detect phosphorylation; however, we observe more banding in samples 
over-expressing E2.  We attempted to determine if RINT1 is phosphorylated in 
complex with E2.  First, we addressed the possibility that the higher mobility 
banding is due to antibody background.  In all experiments a BPV-1 E2 
monoclonal antibody (B201) is used that recognizes an N-terminal fragment of 
the protein.  This antibody is known to recognize several background bands in  
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Table 3.2 Summary of BPV-1 E2 Point Mutants  
 
Lesion 
Transcriptional 
Activity 
Protein 
Interaction 
D24A ++ 
 
E39G - 
 
A46E +++ 
 
Q66R - 
 
L79A -/+ 
 
F87S - 
 
W92R - 
 
S93P - 
 
W99C - TFIIB 
P106S - 
 
N127Y + 
 
W130R ++ hCHLr1 
Y131H + 
 
W145R - Gps2 
E176G + 
 
R179G + 
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immunoblot experiments.  To address this we immunoprecipitated E2 using a 
rabbit N-terminal polyclonal antibody (II-1) and probed for RINT1 with two 
separate antibodies.  In samples precipitated with both II-1 and B201 antibodies, 
RINT1 was efficiently co-precipitated.  Additionally, higher mobility bands were 
observed in samples co-precipitated with either antibody.  There was also no 
difference between hemagglutinin tagged or FLAG tagged RINT1 (Fig 3.5a).  
B201 was used to co-precipitate E2 and RINT1 and the complex was treated on 
beads with CIP.  In RINT1 input immunoblot, co-transfection of RINT1 and E2 
resulted in a non-distinct series of bands migrating slower than the expected 
mobility of RINT1 (Fig 3.5b).  Co-precipitation of RINT1 with an E2 antibody 
clarified these higher molecular weight bands into more than five distinct bands 
of higher molecular weight than RINT1.  Treatment of the sample with CIP did 
not have any effect on this banding pattern (Fig 3.5b).  
RINT1 Does Not Interact with the BPV-1 Genome 
There is no clear suggestion based on RINT1 biology in the literature as to what 
effects RINT1 may have on E2 function.  Many of E2s functions in the viral life 
cycle are mediated by interaction with the viral genome.  Our first step in 
determining the functional significance of this interaction was to determine if 
RINT1 interacts with E2 in complex with DNA.  To address this, ID13 cells, which 
episomally maintain BPV-1 genomes, were transfected with a RINT1 expression 
construct and then ChIP analysis was performed.  As expected, E2 interacts  
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Figure 3.5 E2 co-precipitates higher molecular weight RINT1.  A C33a 
cells were co-transfected with HA-RINT1 or myc-RINT1 and wild 
type E2.  24 hours post transfection cells were lysed and 
complexes were precipitated with either rabbit E2 (II-1) or mouse 
E2 (B201) antibodies.  Precipitates were then probed for RINT1 
using either anti-HA or anti-myc antibodies.  B Cells were 
transfected with HA-RINT1 and the following day 
immunoprecipitated with E2 B201.  Precipitates complexes were 
split and treated with calf intestinal phosphatase (CIP) or bovine 
serum albumin (BSA).  Precipitates were probed for RINT1 using 
an anti-HA antibody.  
  
A 
B 
Figure 3
weight RINT1.
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quite robustly with BPV-1 genomes (Fig 3.6) as detected by amplifying 
precipitated complexes using BPV-1 LCR primers.  However, neither of two 
RINT1 antibodies used was able to co-precipitate BPV-1 genomes in complex 
with RINT1 (Fig 3.6). 
RINT1 Over-Expression Does not Affect E2 Dependent Reporter Activation 
Interaction with the panel of transcriptionally defective mutants did not 
conclusively determine if RINT1 plays a role in E2 dependent transcriptional 
activation.  Two transcriptionally defective mutants in close proximity do not 
appear to interact efficiently or with high affinity to RINT1.  We addressed the 
possibility that RINT1 may be a limiting factor in E2 dependent transcription by 
using a luciferase reporter assay.  Upon transfection of wild type E2, an 80 fold 
increase in luciferase activity was detected (Data Not Shown, Fig 3.7a).  
Transfection of RINT1 in the absence of E2 showed no increase in luciferase 
activity over reporter alone (Fig 3.7a).  While TFIIB, which has previously been 
demonstrated to enhance E2 dependent transcription, increased luciferase 
activity nearly two fold over E2 alone, co-transfection of RINT1 had no effect.  
Luciferase activity in the presence of RINT1 was no different than E2 alone (Fig 
3.7a).  It is possible that over-expression of RINT1 may have a negative effect on 
E2 dependent transcription or positive effects may be squelched at high levels of 
RINT1 transfection.  To determine if this is the case, we performed a dose 
response starting at a ten-fold lower concentration than in the previous  
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Figure 3.6 RINT1 Does not Interact with BPV1 Genomes.  ID13 cells were 
transfected with RINT1.  24 hours post transfection, cells were 
crosslinked, lysed and immunprecipitated with control IgG, E2 
(B201), or one of two RINT1 antibodies rabbit peptide 2074, or anti 
RINT1 (79).  Precipitates were amplified using primers for the BPV-
1 LCR.  
  
Figure 
with BPV1 genomes.
 
3.6 RINT1 does not interact 
 
134 
135 
 
  
Figure 3.7 RINT1 does not affect E2 dependent transcription.  A and a 
combination of E2, RINT1, or TFIIB.  24 hours post transfection 
cells harvested and luciferase detected.  One way ANOVA was 
performed with Bonferoni’s post hoc test ** p<0.01. B C33a cells 
were transfected with E2 responsive luciferase reporter, E2 and 
either 100ng, 200ng, or 300ng of RINT1. Luciferase activity was 
detected 24 hours post transfection.  
  
A 
B 
Figure 
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experiment.  In contrast to transfection of 1 µg of RINT1, transfection of 0.1 µg 
led to a 1.5 fold increase in luciferase activity.  This increase, however, was not 
observed in any higher concentrations as both transfections of 0.2 µg and 0.3 µg 
resulted in no increase over E2 alone (Fig 3.7b).  Overexpression is useful in 
determining if proteins of interest are capable of stimulating a particular pathway, 
in this case RINT1 in E2 dependent transcription.  This does not rule out the 
importance of RINT1 in E2 dependent transcription and to determine if RINT1 is 
truly limiting for E2 dependent transcription the effect of RINT1 depletion on 
reporter activation should be addressed. 
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Discussion 
The papillomavirus E2 regulatory factor functions in nearly every process in the 
productive viral life cycle.  This small protein accomplishes this functional 
diversity through its interaction with a myriad of cellular factors.  Here we discuss 
RINT1, a protein which we have identified first through a screen for other proteins 
interacting with the cellular cohesion factor hCHLR1, and then through a directed 
binding assay with BPV-1 E2.  RINT1 also displays diversity with its known 
complexes and interaction partners, having potential roles in the response to 
DNA damage (206), vesicular trafficking (6, 8, 79, 182), and hTERT independent 
control of telomere length (102).  While the viral oncogene E7 (59, 156, 212) and 
the minor capsid protein L2(22, 109) have been demonstrated to interact with 
some of the common components of these pathways, there have been no reports 
to date placing either of these proteins in complexes with RINT1.  Nor has E2 
been shown to be involved in any of the RINT1 dependent processes.  The novel 
interaction between BPV-1 and E2 may reveal a new role for E2 in the viral life 
cycle.   
Identification that the interaction takes place in the N-terminus indicates that E2 
may still be able to contact DNA in complex with RINT1.  It is not uncommon for 
E2 to recruit factors to the promoter or replication origin.  However, this is unlikely 
given that we were unable to detect RINT1 interaction on BPV1 genomes.  The 
inability of certain transcriptionally defective mutants to interact with RINT1 
suggests that like Brd4, RINT1 may be important for E2 dependent transcription.  
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If RINT1 is involved in transcriptional activation, its endogenous protein levels 
may saturate complex formation with E2.  This may explain why overexpression 
does not increase luciferase activity. siRNA mediated depletion of RINT1 and its 
effect on E2 dependent transcription and other E2 dependent viral functions 
would be interesting to explore.  
Mutation of residues D24, A46, and N127 appear to increase interaction with 
RINT1.  These three residues are not in close proximity in the structure model of 
the BPV-1 E2 N-terminus and only N127 is within the deletion fragment of E2 
that we show is important for RINT1 interaction.  These three residues could 
however, disrupt the interaction of E2 with another protein that inhibits E2 
interaction with RINT1.  Alternatively, mutation of these residues could promote a 
stronger interaction with a co-factor which strengthens the E2-RINT1 interaction.  
In contrast, the remaining transactivation mutants that were tested displayed 
reduced binding capacity for RINT1 including W130R which is unable to interact 
with hCHLr1.  If RINT1 forms a complex with hCHLr1 and E2, that may explain 
the reduced binding for the E2 W130R mutant. However, we cannot ignore the 
possibility that the reduced interaction between RINT1 and W130R, Y131H, and 
R176G may be a function of the chemiluminescent imaging system which 
normalizes images to strong band intensities such as N127Y.  However, inability 
to interact with hCHLr1 may also explain the reduced interaction for Y131H as 
well which is in close proximity to W130R.  R176G and R179G are also near the 
hCHLr1 interaction domain, although their role in interaction with hCHLr1 if any is 
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unclear.  R179G in particular was consistently reduced in RINT1 interaction.  
This suggests that this mutant may be a useful tool to identify the biological 
significance of the interaction.  Previous studies using this mutation have 
demonstrated that it is competent for transient replication partially deficient for 
transcriptional activation (70).  Although a role for RINT1 in episomal genome 
maintenance has not yet been ruled out, the lack of RINT1 interaction with the 
genome would argue against this possibility. 
The presence of multiple bands at incrementally larger molecular weight 
indicates that RINT1 may be modified in complex with E2.  These higher 
molecular weight bands are not detected in RINT1 input.  The study that initially 
characterized RINT1 has shown that it migrates as a doublet and they suggest 
that this may be due to initiation at an upstream non-AUG start site (206).  While 
they do not confirm this, they also claim that following treatment with alkaline 
phosphatase, there was no change in mobility of the slower migrating band which 
is consistent with our findings here.  The incremental ladder that is 
immunoprecipitated suggests that there may be another type of modification.  
Several candidates include ubiquitination, neddylation or sumoylation.   
The most recent studies on RINT1 biology have converged on the vesicular 
transport pathway as a critical role for RINT1.  This pathway seems incongruous 
for a viral regulatory factor involved in transcription, replication and maintenance.  
Immunofluorescent staining of HeLa cells over-expressing both RINT1 and wild 
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type E2 resulted in ER/Golgi staining for each protein (Data not shown).  While 
this is typical staining for RINT1 as previously demonstrated, BPV-1 E2 is a DNA 
binding factor that encodes two nuclear localization sequences and is found in 
the nucleus in almost all cases.  It appears that RINT1 may recruit E2 to the ER 
or Golgi compartments.  This staining pattern is similar to what was observed 
upon transfection of both syntaxin-18 and BPV-1 L2.  It is interesting that two 
viral proteins with distinct functions would localize to the same complex.  It is 
unclear if L2-syntaxin-18 and E2-RINT1 are in complex together at the same 
time.    
The results presented here demonstrate a novel interaction between the cellular 
factor RINT1 and BPV-1 E2.  This interaction appears to be necessary for a 
novel function of E2.  While we were unable to determine the specific function of 
this interaction, we have demonstrated that RINT1 does not interact with DNA.  
While this does not exclude a higher order complex formation it does suggest 
that the interaction may not require the DNA specific activities of E2.  Further, we 
show that RINT1 may be post-translationally modified in complex with E2; it is 
unclear as to the role of this modification on the function of the E2-RINT1 
complex.  These results form a basis for further exploration into the functional 
significance of this interaction.  
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Conclusions 
We demonstrate here a requirement for the histone acetyltransferase proteins 
p300, CBP, and pCAF for E2 dependent transcriptional activation.  Further, we 
show that despite an overlapping substrate pool, all three of these proteins have 
unique functions.  Our data presented here suggest that there may be two 
phases of complex assembly on the viral LCR.  First, p300 interacts with and 
modifies either chromatin on the viral genome or E2.  This initial modification by 
p300 facilitates the interaction of E2 to with viral DNA.  This is one point of 
functional specificity for p300; neither CBP nor pCAF are necessary for E2 to 
efficiently interact with DNA. Second, E2 recruits CBP to the genome.  p300 
acetylates E2 in vitro and it appears that both p300 and CBP acetylate E2 in 
RPE-1 cells.  E2 may be acetylated by p300 primarily and acetylation of E2 by 
CBP capable of compensating for the loss of p300.  It is unclear if E2 is 
acetylated by p300 after binding to the genome or if acetylation by p300 results in 
higher DNA interaction efficiency; however, acetylation of E2 is necessary for 
transcriptional activation.  We believe that acetylation of E2 results in the creation 
of an interaction surface to which a protein containing a bromodomain, such as 
Brd4, may bind.   
The phenomenon of Crm1 independent accumulation of E2 in the cytosol is 
intriguing.  It is possible that acetylation of residues 111 and 112 are necessary 
for retaining E2 in the nucleus.  These two residues are highly conserved which 
would indicate their importance through papillomavirus evolution.  However, at 
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this time we are unable to draw conclusions about the importance of cytosolic 
and the mechanism through which it is localized.  It may be related to passive 
diffusion of E2 from the nucleus; however, we cannot yet rule out deficiencies in 
nuclear import due to a weakened NLS. Alternatively, E2 may be mislocalized as 
due to an inefficient interaction with a nuclear protein in the absence of 
acetylation resulting in loss from active transcriptional complexes and 
subsequent diffusion from the nucleus. 
The novel interaction between E2 and RINT1 is interesting as well.  While we 
were unable to generate positive functional data that would have identified the 
role of this interaction in the viral infection, we were able to rule out transcription.  
Studies outlining the cellular functions of RINT1 also indicate some interesting 
possibilities for functional significance. These include some functions that E2 was 
thought not to participate in such as vesicle trafficking and telomere 
maintenance.   
Functional studies of both E2 acetylation and the interaction between E2 and 
RINT1 could result in new potential vaccines and therapies.  BPV has long been 
a model system to characterize the mechanism of papillomavirus transcription.  
This system allows the study of E2 dependent transcriptional activation without 
the antagonistic effects of early promoter repression as seen in human 
papillomavirus systems.  It has been shown that E2 is still capable of activating 
transcription from the HPV LCR (103) so many of the effects observed for BPV-1 
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E2 dependent transcriptional activation may be transferrable to HPV E2 
dependent transcriptional activation.  These effects may however be limited to 
differentiation dependent transcription; this report suggests that requirement for a 
C/EBPα binding site downstream of the E6/E7 transcriptional initiation site and 
high p300 levels (p300 levels increase in suprabasal cells) are necessary for E2 
dependent activation.   
Many of the cellularly encoded proteins that interact with BPV-1 E2 are likely to 
interact with HPV type E2 proteins as well given a high sequence homology.  In 
that regard understanding which proteins interact with BPV-1 E2 and how they 
affect E2 function may also allow a better understanding of HPV E2 transcription.  
Further, it has been demonstrated that the function of E2, activation or 
repression, is at least partly related to the position of the E2 binding sites in 
relation to the transcriptional start site.  Using the knowledge of protein 
interactions and DNA binding, it may be possible to skew the HPV-16 
transcription program to specifically inhibit all viral transcription in basal 
keratinocytes.  This would cause the cell to senesce due to lack of p53 and pRB 
inhibition by E6 and E7 respectively (65).  While this would not clear viral 
infection it would be an effective method to control pathology.  Similarly, inhibition 
of E2 acetylation through inhibition of its interaction with p300, or direct inhibition 
of acetylation, would interfere with transcriptional activation.  In addition to 
disruption of transcriptional activation in basal cells, this may also inhibit 
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expression of late genes in differentiated tissue which would then prevent 
transmission of the virus.   
Given the lack of therapeutic vaccines, further study into the nature of HPV 
transcription is warranted.  Differentiation between activation and repression 
could lead to therapies that could selectively inhibit viral activation while 
continuing to repress viral oncogene expression.  This in turn could provide an 
avenue to selectively induce apoptosis in HPV tumor cells without introducing 
exogenous E2.  Several groups have attempted similar approaches by infecting 
cells with adenovirus expressing E2 proteins (15, 68).  These studies 
demonstrate that selective killing of HPV tumor cells through E2 expression is a 
promising therapy.  The possibility of developing a small molecule that may 
accomplish this without the need for exogenous introduction of E2 through viral 
infection is intriguing. 
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Future Direction 
Further characterization of HATs on the viral LCR would be very informative in 
determining their overall importance in E2 dependent viral transcription.  Some of 
the data presented in this work are preliminary results that need to be repeated 
several more times and optimized including the quantitative ChIP that 
demonstrates that E2 DNA binding is p300 dependent.  HAT depletion in virally 
transformed cells including ID13 and C127-A3 was very inconsistent.  
Optimization of this protocol would generate data for both this ChIP assay, 
analysis of acetylated Histones on the genome, as well as detection of E6 RNA 
transcript.  This was in progress upon the completion of this work.  In addition to 
these experiments, it would be interesting to determine the timing of early events 
in E2 dependent transcription.  It is unclear how p300 enhances E2 interaction 
with DNA, it would be informative to use E2 K/R mutants to ask the following 
questions 1) can E2 still interact with p300? 2) is acetylation of E2 necessary to 
facilitate E2 binding? And 3) do p300 and E2 interact with DNA as a complex or 
is the modification of chromatin by p300 sufficient for E2 to interact.  The roles of 
CBP and pCAF are also unclear and more work is needed to determine their 
unique roles in E2 dependent transcription.   
We were able to confirm acetylation of E2 on 14 sites in vitro.  This is most likely 
does not happen in cells.  It appears through the screening of lysine to arginine 
mutants that some of these lysines are acetylated in vivo.  To confirm which 
lysines are acetylated in a physiological setting, E2 must be purified from 
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mammalian cells and then acetylation sites identified by proteomic analysis.  
Subsequent analysis of combinatorial mutations would be informative for 
understanding the functional significance of E2 acetylation.  Additionally, more 
work must be done to determine what role if any K111 and K112 play in the 
regulation of E2 localization.  It might be interesting to examine the ability of 
these mutants to be imported into the nucleus.  Finally, how does acetylation 
affect transcription?  We postulate here that this is through interaction with a co-
factor such as Brd4.  Currently, we have no evidence to support this or 
interaction with any other protein.   
Primarily biochemical interaction data was presented here regarding the 
interaction between E2 and RINT1.  First, optimization of RINT1 depletion is 
critical to determining its role in the viral life cycle.  Simple experiments such as 
depletion of syntaxin-18 might identify if RINT1 interacts with E2 in this complex.  
If it does, this implicates E2 in the vesicular trafficking. It is known that the minor 
capsid protein L2 interacts with DNA, syntaxin-18 and is capable of entering the 
nucleus on its own.  Perhaps complex formation between E2 and RINT1 links E2 
to Zw10 and dynein, facilitating its transport from the ER membrane.  Given that 
E2 point mutants K111R and K112R are mislocalized to the cytosol, in a possibly 
ER/Golgi staining pattern, it might be interesting to address a role for these 
residues in RINT1 interaction.  RINT1 interacts with Rad50 in the nucleus in 
G2/M phase.  A time course observing this interaction might indicate if RINT1/E2 
is involved in complex with this protein.  RINT1 interacts with both Rad50 and 
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p130 in the maintenance of telomere length by the ALT pathway.  Co-
precipitation with p130 could help to determine the role played by RINT1 in this 
process.  Additionally, observing telomere length in the presence or absence of 
E2 and an E2 point mutant that does not interact with RINT1 would be a direct 
way to answer this question functionally. 
E2, RINT1 and hCHLr1 all interact, however their ability to form a ternary 
complex is unknown.  In addition to determination the specific role of the 
interaction between E2 and RINT1, it would be interesting to identify reasons that 
RINT1 interacts with hCHLr1 and if this complex interacts functionally with E2.  
E2 interaction with RINT1 is not dependent on hCHLr1 given that the E2 mutant 
W130R, which does not bind hCHLr1, is competent for RINT1 binding.  However 
this does not exclude RINT1 as an accessory factor to facilitate loading of E2 and 
BPV genomes onto chromatin.   
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